



AMERICAN ACADEMY™
OF OPHTHALMOLOGY

Protecting Sight. Empowering Lives.™

Corneal Edema and Opacification Preferred Practice Pattern®

Secretary for Quality of Care
Timothy W. Olsen, MD

Academy Staff
Ali Al-Rajhi, PhD, MPH
Andre Ambrus, MLIS
Doris Mizuiri
Rachel Lastra
Flora C. Lum, MD

Medical Editor: Susan Garratt

Approved by: Board of Trustees
September 22, 2018

© 2018 American Academy of Ophthalmology®
All rights reserved

AMERICAN ACADEMY OF OPHTHALMOLOGY and PREFERRED PRACTICE PATTERN are registered trademarks of the American Academy of Ophthalmology. All other trademarks are the property of their respective owners.

Preferred Practice Pattern® guidelines are developed by the Academy's H. Dunbar Hoskins Jr., MD Center for Quality Eye Care without any external financial support. Authors and reviewers of the guidelines are volunteers and do not receive any financial compensation for their contributions to the documents. The guidelines are externally reviewed by experts and stakeholders before publication.

Correspondence:
Ali A. Al-Rajhi, PhD, MPH, American Academy of Ophthalmology, P. O. Box 7424, San Francisco, CA 94120-7424. E-mail: aalrajhi@aao.org.

CORNEA/EXTERNAL DISEASE PREFERRED PRACTICE PATTERN DEVELOPMENT PROCESS AND PARTICIPANTS

The **Cornea/External Disease Preferred Practice Pattern® Panel** members wrote the Corneal Edema and Opacification Preferred Practice Pattern® guidelines (PPP). The PPP Panel members discussed and reviewed successive drafts of the document, meeting in person twice and conducting other review by e-mail discussion, to develop a consensus over the final version of the document.

Cornea/External Disease Preferred Practice Pattern Panel 2017–2018

Steven P. Dunn, MD, Co-chair
Francis S. Mah, MD, Co-chair
Esen K. Akpek, MD
Guillermo Amescua, MD
Marjan Farid, MD
Francisco J. Garcia-Ferrer, MD
Amy Lin, MD, Cornea Society Representative
Michelle K. Rhee, MD
Divya M. Varu, MD
David C. Musch, PhD, MPH, Methodologist

The **Preferred Practice Patterns Committee** members reviewed and discussed the document during a meeting in June 2018. The document was edited in response to the discussion and comments.

Preferred Practice Patterns Committee 2018

Robert S. Feder, MD, Chair
Roy S. Chuck, MD, PhD
Steven P. Dunn, MD
Christina J. Flaxel, MD
Francis S. Mah, MD
Randall J. Olson, MD
Bruce E. Prum, Jr., MD
David K. Wallace, MD, MPH
David C. Musch, PhD, MPH, Methodologist

The Corneal Edema and Opacification PPP was then sent for review to additional internal and external groups and individuals in July 2018. All those returning comments were required to provide disclosure of relevant relationships with industry to have their comments considered. Members of the Cornea/External Disease Preferred Practice Pattern Panel reviewed and discussed these comments and determined revisions to the document.

FINANCIAL DISCLOSURES

In compliance with the Council of Medical Specialty Societies' Code for Interactions with Companies (available at www.cmss.org/codeforinteractions.aspx), relevant relationships with industry are listed. The Academy has Relationship with Industry Procedures to comply with the Code (available at www.aao.org/about-preferred-practice-patterns). A majority (70%) of the members of the Cornea/External Disease Preferred Practice Pattern Panel 2017–2018 had no financial relationships to disclose.

Cornea/External Disease Preferred Practice Pattern Panel 2017–2018

Esen K. Akpek, MD: Allergan – Grant Support; KeraLink, Novartis Pharma AG – Consultant/Advisor
 Guillermo Amescua, MD: No financial relationships to disclose
 Steven P. Dunn, MD: No financial relationships to disclose
 Marjan Farid, MD: Allergan, Bio-Tissue, Inc., CorneaGen – Consultant/Advisor
 Francisco J. Garcia-Ferrer, MD: No financial relationships to disclose
 Amy Lin, MD: No financial relationships to disclose
 Francis S. Mah, MD: Alcon Laboratories, Inc., Allergan – Consultant/Advisor
 David C. Musch, PhD, MPH: No financial relationships to disclose
 Michelle K. Rhee, MD: No financial relationships to disclose
 Divya M. Varu, MD: No financial relationships to disclose

Preferred Practice Patterns Committee 2018

Robert S. Feder, MD: No financial relationships to disclose
 Roy S. Chuck, MD, PhD: Novartis Pharmaceuticals – Consultant/Advisor
 Steven P. Dunn, MD: No financial relationships to disclose
 Christina J. Flaxel, MD: No financial relationships to disclose
 Francis S. Mah, MD: Alcon Laboratories, Inc., Allergan – Consultant/Advisor
 David C. Musch, PhD, MPH: No financial relationships to disclose
 Randall J. Olson, MD: No financial relationships to disclose
 Bruce E. Prum, Jr., MD: No financial relationships to disclose
 David K. Wallace, MD, MPH: No financial relationships to disclose

Secretary for Quality of Care

Timothy W. Olsen, MD: No financial relationships to disclose

Academy Staff

Ali Al-Rajhi, PhD, MPH: No financial relationships to disclose
 Andre Ambrus, MLIS: No financial relationships to disclose
 Susan Garratt: No financial relationships to disclose
 Rachel Lastra: No financial relationships to disclose
 Flora C. Lum, MD: No financial relationships to disclose
 Doris Mizuri: No financial relationships to disclose

The disclosures of relevant relationships to industry of other reviewers of the document from January to October 2018 are available online at www.aao.org/ppp.

TABLE OF CONTENTS

OBJECTIVES OF PREFERRED PRACTICE PATTERN GUIDELINES	P221
METHODS AND KEY TO RATINGS	P222
HIGHLIGHTED FINDINGS AND RECOMMENDATIONS FOR CARE	P223
INTRODUCTION	P224
Disease Definition	P224
Corneal Edema	P224
Corneal Opacification.....	P225
Patient Population.....	P226
Clinical Objectives	P226
BACKGROUND	P227
Natural History	P227
Rationale for Treatment.....	P227
CARE PROCESS	P227
Patient Outcome Criteria	P227
Diagnosis	P227
History	P227
Examination.....	P231
Diagnostic Evaluation.....	P233
Management	P237
General Treatment Goals.....	P237
Medical Management of Corneal Edema	P237
Surgical Management of Corneal Edema.....	P238
Medical Management of Corneal Opacification	P238
Surgical Management of Corneal Opacification.....	P248
Follow-up Evaluation	P264
Provider and Setting	P264
Counseling and Referral	P264
Socioeconomic Considerations.....	P265
APPENDIX 1. QUALITY OF OPHTHALMIC CARE CORE CRITERIA	P267
APPENDIX 2. INTERNATIONAL STATISTICAL CLASSIFICATION OF DISEASES AND RELATED HEALTH PROBLEMS (ICD) CODES	P269
APPENDIX 3. DETERMINATION OF INTRAOCULAR PRESSURE IN DISEASED OR POSTSURGICAL CORNEAS	P271
LITERATURE SEARCHES FOR THIS PPP	P273
RELATED ACADEMY MATERIALS	P275
REFERENCES	P276

OBJECTIVES OF PREFERRED PRACTICE PATTERN® GUIDELINES

As a service to its members and the public, the American Academy of Ophthalmology has developed a series of Preferred Practice Pattern® guidelines that **identify characteristics and components of quality eye care**. Appendix 1 describes the core criteria of quality eye care.

The Preferred Practice Pattern® guidelines are based on the best available scientific data as interpreted by panels of knowledgeable health professionals. In some instances, such as when results of carefully conducted clinical trials are available, the data are particularly persuasive and provide clear guidance. In other instances, the panels have to rely on their collective judgment and evaluation of available evidence.

These documents provide guidance for the pattern of practice, not for the care of a particular individual. While they should generally meet the needs of most patients, they cannot possibly best meet the needs of all patients. Adherence to these PPPs will not ensure a successful outcome in every situation. These practice patterns should not be deemed inclusive of all proper methods of care or exclusive of other methods of care reasonably directed at obtaining the best results. It may be necessary to approach different patients' needs in different ways. The physician must make the ultimate judgment about the propriety of the care of a particular patient in light of all of the circumstances presented by that patient. The American Academy of Ophthalmology is available to assist members in resolving ethical dilemmas that arise in the course of ophthalmic practice.

Preferred Practice Pattern® guidelines are not medical standards to be adhered to in all individual situations. The Academy specifically disclaims any and all liability for injury or other damages of any kind, from negligence or otherwise, for any and all claims that may arise out of the use of any recommendations or other information contained herein.

References to certain drugs, instruments, and other products are made for illustrative purposes only and are not intended to constitute an endorsement of such. Such material may include information on applications that are not considered community standard, that reflect indications not included in approved U.S. Food and Drug Administration (FDA) labeling, or that are approved for use only in restricted research settings. The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use, and to use them with appropriate patient consent in compliance with applicable law.

Innovation in medicine is essential to ensure the future health of the American public, and the Academy encourages the development of new diagnostic and therapeutic methods that will improve eye care. It is essential to recognize that true medical excellence is achieved only when the patients' needs are the foremost consideration.

All Preferred Practice Pattern® guidelines are reviewed by their parent panel annually or earlier if developments warrant and updated accordingly. To ensure that all PPPs are current, each is valid for 5 years from the "approved by" date unless superseded by a revision. Preferred Practice Pattern guidelines are funded by the Academy without commercial support. Authors and reviewers of PPPs are volunteers and do not receive any financial compensation for their contributions to the documents. The PPPs are externally reviewed by experts and stakeholders, including consumer representatives, before publication. The PPPs are developed in compliance with the Council of Medical Specialty Societies' Code for Interactions with Companies. The Academy has Relationship with Industry Procedures (available at www.aao.org/about-preferred-practice-patterns) to comply with the Code.

Appendix 2 contains the International Statistical Classification of Diseases and Related Health Problems (ICD) codes for the disease entities that this PPP covers. The intended users of the Corneal Edema and Opacification PPP are ophthalmologists.

METHODS AND KEY TO RATINGS

Preferred Practice Pattern® guidelines should be clinically relevant and specific enough to provide useful information to practitioners. Where evidence exists to support a recommendation for care, the recommendation should be given an explicit rating that shows the strength of evidence. To accomplish these aims, methods from the Scottish Intercollegiate Guideline Network¹ (SIGN) and the Grading of Recommendations Assessment, Development and Evaluation² (GRADE) group are used. GRADE is a systematic approach to grading the strength of the total body of evidence that is available to support recommendations on a specific clinical management issue. Organizations that have adopted GRADE include SIGN, the World Health Organization (WHO), the Agency for Healthcare Research and Quality, and the American College of Physicians.³

- ◆ All studies used to form a recommendation for care are graded for strength of evidence individually, and that grade is listed with the study citation.
- ◆ To rate individual studies, a scale based on SIGN¹ is used. The definitions and levels of evidence to rate individual studies are as follows:

I++	High-quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with a very low risk of bias
I+	Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias
I-	Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias
II++	High-quality systematic reviews of case-control or cohort studies High-quality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal
II+	Well-conducted case-control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal
II-	Case-control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal
III	Nonanalytic studies (e.g., case reports, case series)

- ◆ Recommendations for care are formed based on the body of the evidence. The body of evidence quality ratings are defined by GRADE² as follows:

Good quality	Further research is very unlikely to change our confidence in the estimate of effect
Moderate quality	Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Insufficient quality	Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate Any estimate of effect is very uncertain

- ◆ Key recommendations for care are defined by GRADE² as follows:

Strong recommendation	Used when the desirable effects of an intervention clearly outweigh the undesirable effects or clearly do not
Discretionary recommendation	Used when the trade-offs are less certain—either because of low-quality evidence or because evidence suggests that desirable and undesirable effects are closely balanced

- ◆ The Highlighted Findings and Recommendations for Care section lists points determined by the PPP panel to be of particular importance to vision and quality of life outcomes.
- ◆ All recommendations for care in this PPP were rated using the system described above. Ratings are embedded throughout the PPP main text in italics.
- ◆ Literature searches for the PPP were undertaken in March 2017 and June 2018 in PubMed and the Cochrane Library. Complete details of the literature search are available at www.aao.org/ppp.

HIGHLIGHTED FINDINGS AND RECOMMENDATIONS FOR CARE

The impact of corneal edema on activities of daily living—particularly those influenced by ambient light levels at home, work, and during leisure activities—is often underappreciated. Standard measurement of visual acuity does not give a true representation of the patient’s functional vision.

Reduced vision in cases of corneal opacification is more often related to corneal surface irregularity than to the opacity itself. A refraction over a rigid gas-permeable (RGP) contact lens can be very helpful in determining if visual loss is due to a corneal surface irregularity.

Endothelial function is best evaluated by slit-lamp biomicroscopy examination and may be supported by changes in corneal thickness noted on serial pachymetric measurements performed at the same time of day. Specular microscopy is not a direct measure of endothelial function or functional reserve. When diffuse endothelial guttae are present on slit-lamp biomicroscopy examination, specular microscopy rarely provides any valuable information because it is difficult to image the endothelial cells.

Corneal pachymetry, measured in the morning, is a helpful indicator of the ability of the endothelium to regulate corneal hydration appropriately. Corneas that are abnormally thick in the morning hours may be less able to tolerate proposed intraocular surgery.

If the cataract surgeon or cornea specialist thinks that decompensation, if not imminent, is likely to occur in the near future, a discussion about modifying the intraocular lens (IOL) power calculation is worthwhile to adjust for changes induced by endothelial keratoplasty (specifically a hyperopic shift due to Descemet stripping automated endothelial keratoplasty [DSAEK] and less so with Descemet membrane endothelial keratoplasty [DMEK]). A full discussion of the added risks of subsequent corneal decompensation is very important in this group of patients and helps to shape their expectations with respect to their condition and the surgery.

Endothelial keratoplasty has supplanted penetrating keratoplasty as the procedure of choice in cases of endothelial failure in the absence of corneal scarring because patients achieve more rapid visual rehabilitation and reduction in rejection of the transplanted tissue.

INTRODUCTION

DISEASE DEFINITION

Corneal Edema

Corneal edema is the retention of excess fluid within one or multiple layers of the cornea. See Table 1 for the etiology of corneal edema.

TABLE 1 ETIOLOGY OF CORNEAL EDEMA

	Unilateral	Bilateral
Early Age Onset		
Congenital glaucoma	•	•
Dystrophies:		
CHED – AD (appears now to be a form of PPCD)		•
CHED – AR		•
PPCD		•*
Intraocular inflammation	•	•
Trauma:		
Birth/forceps delivery	•	
Intrauterine	•	
Late-Age Onset		
Acute angle-closure glaucoma	•	•
Dystrophies:		
Fuchs dystrophy		•
PPCD		•*
Hypotony	•	
Hypoxia		•*
Intraocular inflammation/uveitis	•	•
ICE syndrome	•	
Keratitis:		
Infectious	•	
Keratoconus – hydrops	•	
Surgical Trauma:		
Pseudophakic or aphakic bullous keratopathy (unilateral or bilateral)	•	•
Direct injury	•	
Toxicity:		
Amantadine		•
Cancer chemotherapy [†]		•
Chlorhexidine	•	•
Silicone oil	•	
Bupropion		•

* Occasionally unilateral. AD = autosomal dominant; AR = autosomal recessive; CHED = Congenital hereditary endothelial dystrophy; ICE = Iridocorneal endothelial; PPCD = posterior polymorphous corneal dystrophy.

Corneal Opacification

Corneal opacification results from the presence of additional material (e.g., fluid, scar tissue, inflammatory debris, metabolic byproducts) within one or multiple layers of the cornea that is associated with loss of corneal clarity. Possible causes are as follows:

- ◆ Congenital
 - ◆ Axenfeld-Rieger anomaly
 - ◆ Peters anomaly
 - ◆ Sclerocornea
 - ◆ Dermoid
 - ◆ Leukoma
- ◆ Degenerations
 - ◆ Calcific band keratopathy
 - ◆ Crocodile shagreen
 - ◆ Spheroidal degeneration
 - ◆ Salzmann nodular degeneration
 - ◆ Pterygium
 - ◆ Polymorphic amyloid degeneration
- ◆ Dystrophies
 - ◆ Epithelial basement membrane dystrophy
 - ◆ Reis-Bücklers dystrophy
 - ◆ Thiel-Behnke corneal dystrophy
 - ◆ Gelatinous drop-like dystrophy
 - ◆ Lattice corneal dystrophy
 - ◆ Granular corneal dystrophy
 - ◆ Macular corneal dystrophy
 - ◆ Schnyder corneal dystrophy
 - ◆ Congenital hereditary stromal dystrophy
 - ◆ Congenital hereditary endothelial dystrophy (CHED)
 - ◆ Posterior polymorphous corneal dystrophy (PPCD)
 - ◆ Posterior amorphous corneal dystrophy
 - ◆ Fuchs dystrophy
- ◆ Inflammatory and immunologic
 - ◆ Infection (bacterial, fungal, parasitic, and viral)
 - ◆ Interstitial keratitis (nonsterile and sterile)

- ◆ Metabolic
 - ◆ Mucopolysaccharidosis
 - ◆ Mucopolidoses
 - ◆ Lipidosis
 - ◆ Hypolipoproteinemias
 - ◆ Cystinosis
 - ◆ Fabry disease
- ◆ Depositional
 - ◆ Amyloid
 - ◆ Cryoglobulinemia/multiple myeloma
 - ◆ Drugs
 - ◆ Heavy metals
 - ◆ Lipid keratopathy
- ◆ Neoplastic
 - ◆ Conjunctival/corneal intraepithelial neoplasia
 - ◆ Melanosis/melanoma
- ◆ Postsurgical
 - ◆ Corneal wound scarring
- ◆ Post-traumatic injury

PATIENT POPULATION

The patient population includes individuals of any age who have corneal edema or opacification.

CLINICAL OBJECTIVES

- ◆ Assess the degree of vision loss
- ◆ Evaluate the degree of functional impairment and its effect on the patient's activities of daily living
- ◆ Identify the underlying ocular condition responsible for the corneal edema or opacification
- ◆ Assess the potential for progression of the disorder, development of discomfort, and/or improvement of vision
- ◆ Determine which optical, medical, or surgical treatment alternative is most appropriate

BACKGROUND

NATURAL HISTORY

Corneal edema and opacification may or may not be progressive. Conditions that affect primarily the periphery may be subtle and asymptomatic (e.g., Brown-McLean syndrome, Salzmann nodular degeneration), although peripheral conditions can result in central irregularity and astigmatism that may be visually significant. Those conditions that involve the central, pupillary region generally cause symptoms (e.g., Fuchs dystrophy, scarring secondary to disciform keratitis).

RATIONALE FOR TREATMENT

The reduction or elimination of corneal edema or opacification is indicated when it is associated with functional visual loss or discomfort. Chronic epithelial breakdown associated with underlying stromal or endothelial dysfunction may necessitate intervention to stabilize the ocular surface and prevent further complications. Less commonly, cosmesis is an indication for treatment.

CARE PROCESS

PATIENT OUTCOME CRITERIA

- ◆ Reduce the signs and symptoms of corneal edema or opacification
- ◆ Maintain, restore, or improve visual function according to the needs of the patient

DIAGNOSIS

Initial evaluation of the patient with symptoms and signs of corneal edema or opacification should include the relevant aspects of the comprehensive medical eye evaluation.⁵ The diagnosis of corneal edema or opacification is usually based on a typical patient history and characteristic findings. Ancillary testing may be helpful.

History

Questions about the following elements of the patient history may elicit helpful information:

- ◆ Symptoms and signs: blurred or variable vision, often with a diurnal character (worse upon waking and clearer later in the day); photophobia; redness; tearing;

intermittent foreign-body sensation; intense, disabling, or task-disrupting pain, recent history of other ocular surgery/complications.

- ◆ Age of onset: all ages
- ◆ Rapidity of onset: acute symptoms versus gradual or fluctuating presentation

Most conditions associated with edema present gradually over weeks, months, or longer. At times, it may be so gradual that the patient adjusts surprisingly well and is able to function at a much higher level than the slit-lamp biomicroscopic examination might lead one to expect. Exceptions include edema that is due to the following:

- ◆ Elevated intraocular pressure (IOP), often resulting from topical corticosteroid treatment of the underlying corneal disorder
- ◆ Moderate to severe corneal or intraocular inflammation
- ◆ Corneal hydrops associated with keratoconus, other ectatic disorders, and trauma

Noninfectious corneal opacification (e.g., depositional or scarring disorders) develops more gradually in most cases. Exceptions include acute medication-related band keratopathy.^{6,7}

Infectious corneal opacities frequently present acutely.

- ◆ Persistence: transient or permanent
 - ◆ Inflammatory and pressure-related corneal edema often clears as the underlying problem resolves. Neonatal forceps injury, in which a break in Descemet membrane eventually heals and the resulting stromal edema resolves, is another example. If sufficient endothelial damage occurs, corneal edema may recur years later.⁸
 - ◆ Transient blurred vision upon waking in the morning, on humid days, or after taking a shower can occur with edema associated with endothelial dysfunction. Vision is often better later in the day due to evaporation that reduces this edema.
 - ◆ Most noninflammatory corneal opacities are permanent. Inflammatory infiltrates frequently resolve when the underlying cause disappears. Metabolic deposits due to cysteine crystals⁹ and, to a lesser degree, mucopolysaccharidosis,¹⁰ may resolve with treatment.
- ◆ Unilateral or bilateral presentation (e.g., herpes simplex virus keratitis is usually unilateral, whereas corneal dystrophies are typically bilateral)

- ◆ Moderating factors or situations
 - ◆ Low humidity and modest air movement may lead to visual improvement with endothelial dysfunction.
 - ◆ Visual acuity and visual function may not necessarily correlate with one another. For example, a patient with mild edema associated with Fuchs dystrophy or opacification related to granular dystrophy may have visual acuity of 20/40 or better but may not be able to drive because of disabling glare. Unshielded fluorescent lighting or reflections off surfaces with a high luster and computer screens may cause problems with activities of daily living.¹¹ Higher order aberrations with resulting visual distortions may also result from even mild edema associated with Fuchs dystrophy.¹²
 - ◆ Contact lenses (particularly rigid gas-permeable [RGP] lenses) may be able to improve visual function by creating a smoother and more regular refractive surface.
- ◆ Ocular history
 - ◆ Corneal edema:
 - Acute angle-closure or chronic glaucoma
 - Chemical and traumatic injury
 - Infection
 - Inflammation
 - Intraocular or keratorefractive surgery
 - Laser iridotomy
 - Keratoconus
 - Ocular or periocular trauma (blunt or penetrating)
 - ◆ Corneal opacification:
 - Chemical, thermal, and traumatic injury
 - Infection
 - Inflammation
 - Intraocular and keratorefractive surgery
- ◆ Medical history
 - ◆ Corneal edema:

- Inflammatory conditions associated with uveitis (e.g., sarcoidosis, ankylosing spondylitis)
- ◆ Corneal opacification:
 - Developmental
 - Metabolic/hereditary (e.g., mucopolysaccharidosis, cystinosis)
 - Immune-mediated diseases (e.g., rheumatoid arthritis, interstitial keratitis, Stevens-Johnson syndrome, ocular mucous membrane pemphigoid [OMMP])
 - Malabsorption syndromes (e.g., following colon resection, bowel surgery, hepatobiliary illness)
- ◆ Topical and systemic medications
 - ◆ Corneal edema:
 - Amantadine for neurologic disease may produce a reversible endothelial dysfunction if used for a short period or a permanent problem if used long term.¹³⁻¹⁵
 - When used in surgical preparation for facial trauma or reconstructive and cosmetic facial surgery, inadvertent exposure of the cornea to topical chlorhexidine preparation may cause toxicity that predisposes to endothelial failure.¹⁶
 - Topical carbonic anhydrase inhibitors
 - Bupropion
 - ◆ Corneal opacification:¹⁷
 - Amiodarone^{18,19}
 - Dietary calcium supplementation²⁰
 - Periocular radiation^{21,22}
 - Various chemotherapeutic agents²³⁻²⁵
 - Rho kinase inhibitor verticillate changes^{17,26}
- ◆ Trauma: blunt or penetrating injury to the eye or periocular region, forceps delivery, chemical injury
- ◆ Contact lens wear: rationale, type of lens, wear time, and cleaning routine

- ◆ Family history: patients may be aware of a family history or may relate that a relative had a cloudy cornea; required corneal transplantation; or had repeat episodes of pain, tearing, and photophobia.
- ◆ Social history
 - ◆ Sun exposure at work (e.g., farming, construction) or leisure activity (e.g., boating, golfing) may be related to pterygium development.
 - ◆ Travel may increase exposure to unusual infectious agents.
 - ◆ Exposure to domesticated and nondomesticated animals may increase exposure to unusual infectious agents (e.g., *Brucella*, *Borellia burgdorferi*/Lyme disease).
 - ◆ Diet or dietary deficiencies (e.g., vitamin A deficiency from malabsorption syndromes) may predispose to nutritional problems.
 - ◆ Chemical exposure (longstanding and new)

Examination

A comprehensive examination of the eye and adnexa is necessary to determine the etiology of many cases of corneal edema or opacification. Particularly relevant aspects of the examination are described below.

- ◆ Visual acuity: this should be performed under standard ophthalmic lighting conditions, with and without correction. Pinhole testing and manifest refraction should be done to assess best-corrected visual potential. Furthermore, pinhole near testing or potential acuity meter to assess visual potential is important prior to any surgical treatment decision.
 - ◆ Comparison of visual acuity measurement and functional status
 - ◆ Glare testing
- ◆ External examination
 - ◆ Evidence of proptosis, ptosis, lagophthalmos, or floppy eyelid syndrome
 - ◆ Lid or facial asymmetry, scarring, and malfunction (e.g., poor blink or lid closure due to facial palsy)
 - ◆ Miscellaneous: pupil responses, corneal diameter, dry eye evaluation
- ◆ Slit-lamp biomicroscopy examination
 - ◆ Unilateral or bilateral abnormalities
 - ◆ Diffuse or localized edema

- ◆ Primarily epithelial or stromal edema
- ◆ Evidence of epithelial breakdown, stromal infiltration, epithelial ingrowth, striae, focal thickening, thinning, scarring, interface haze, striae or inflammation, or stromal vascularization or deposits
- ◆ Evidence of guttae; Descemet membrane folds, tears, or detachment; endothelial vesicles; keratic precipitates; pigment; peripheral anterior synechiae
- ◆ Involvement of host tissue (or donor-tissue only), if there is a corneal transplant
- ◆ Evidence of sectoral corneal edema and a cluster or line of KP (as with endotheliitis), or an anterior chamber reaction
- ◆ Use of various slit-lamp techniques such as sclerotic scatter, specular reflection, or indirect illumination to evaluate all layers of the cornea
- ◆ Status, shape, and position of the pupil and iris
 - Sphincter rupture as evidence of past trauma
 - Iridocorneal adhesions, iris transillumination defects, peripheral anterior synechiae, or posterior synechiae as evidence of past trauma, inflammation, or surgery
 - Evidence of intraocular trauma (nonsurgical and surgical)
 - Intraocular lens (IOL) capture by iris
- ◆ Healed or recent corneoscleral wounds, evidence of keratorefractive procedures, areas of scleral thinning associated with previous surgery, surgical devices, and signs of intraocular inflammation.
- ◆ Status and position of the crystalline lens or IOL and any other intraocular device
- ◆ Evidence of past keratorefractive procedures
- ◆ IOP
 - ◆ Goldmann applanation tonometry can be less reliable in abnormal corneas. Intraocular pressure can also be assessed using alternative methods or devices such as a pneumotonometer, handheld electronic applanation tonometer, dynamic contour tonometer, combined application applanation tonometer, ocular response analyzer, rebound tonometer, or digital palpation.
- ◆ Fundus examination
 - ◆ Chronic serous choroidal detachment or retinal detachment may lead to hypotony and secondary corneal edema.

- ◆ B-scan ultrasonography may be necessary to assess the posterior segment.
- ◆ Gonioscopy
 - ◆ Retained nuclear fragments, foreign bodies, or presence of iridocorneal adhesions as seen in ICE syndrome or Axenfeld-Rieger anomaly

Diagnostic Evaluation

Observations from the comprehensive eye examination are augmented by various tests.

- ◆ Potential acuity meter

The potential acuity meter projects a tiny eye chart directly onto the macula in an effort to bypass anterior segment pathology (specifically corneal opacities and cataracts). A small “window” is necessary for the image to reach the retina. The test can be helpful when the patient can read farther down on the eye chart than he or she was able to do in a refracting lane or similar testing situation. This indicates that there is a good chance that vision may improve if the pathologic condition is corrected. A poor result, however, does not necessarily indicate poor visual potential, since the anterior segment pathology may be obstructing the optical pathway or potentially correctable cystoid macular edema may be present. Pinhole vision using an illuminated near card in a darkened room can be used in the same way to assess potential acuity.

- ◆ Rigid contact lens over-refraction

Disruption of the central or paracentral ocular surface due to microcystic edema or scarring can have a surprisingly large impact on vision. These changes may actually have a greater impact than an underlying opacity. The easiest way to differentiate between these two problems is to measure the patient’s best-corrected vision with eyeglasses and then with an RGP contact lens. This can be quickly done in the office by obtaining a set of keratometry measurements, determining the average K reading, and then fitting the RGP lens slightly flatter than this measurement. Over-refraction with spherical lenses is then performed. Mire-pattern irregularity should be specifically noted, because this correlates well with the amount of surface irregularity. Improved vision with the RGP lens but not the eyeglasses suggests that the irregular surface is a major factor in a patient’s reduced vision.

- ◆ Pachymetry

The measurement of corneal thickness continues to evolve as new approaches and devices become available. Ultrasonic pachymeters (10–20 MHz), utilizing a speed

of sound of 1636 to 1640 m/second, typically provide information about a single location on the cornea (i.e., the central cornea). Their range is often limited to between 200 and 1000 μm . Most probes do not have a fixation light, so results can fluctuate from visit to visit because of positioning rather than progression of the disease. With training and careful positioning and probe angulation (kept at 90°), an interobserver standard deviation of 12 μm and variability of less than 2% can be achieved.²⁷ When consistency, precise serial comparison, and peripheral measurements are important, optical coherence tomography (OCT) and Scheimpflug imaging may provide greater accuracy. Both technologies, however, use light and lose accuracy and resolution as stromal edema or opacification increases. The ultrasound biomicroscope (50–70 MHz probes) provides the most accurate measurements when there is significant stromal edema.

Measurements taken with different types of devices are not directly comparable in clinical practice. Comparisons between different instruments have demonstrated varied results, though most large studies report that anterior segment optical coherence tomography (AS-OCT) measurements of central corneal thickness were systematically lower than ultrasound measurements by between 7 and 26 μm .²⁸⁻³²

The greater availability of ultrasonic pachymetry has resulted in a better appreciation of the wide variability of normal corneal thickness. This has made it harder to predict which corneas might decompensate after anterior segment surgery. The risk of corneal failure following cataract surgery is associated with several factors, including 1) a patient history including glare or blurred morning vision that improves during the day, 2) a cornea that demonstrates microcystic edema, stromal thickening, or confluent guttae by slit-lamp biomicroscopic examination, and/or 3) a cornea that demonstrates low central endothelial cell counts by specular microscopy. Intraocular pressure and osmolarity of the tear film are factors that influence normal corneal thickness. Gradual thinning of the cornea with age (6–10 μm per decade) has been demonstrated as well.^{33,34}

- ◆ Topography

The topographic evaluation can help assess irregular astigmatism that may be caused by the corneal edema or scar. In the setting of peripheral lesions, the degree of central irregularity seen on the topographic map may help determine management options. (See Corneal Ectasia PPP.³⁵)

Slit-lamp imaging systems are designed to assess the topographic characteristics of the anterior and posterior corneal surfaces and provide measurements of corneal

thickness. The tomographic capability can enable assessment of the depth of corneal opacification, which can aid in surgical planning. Thickness or pachymetric mapping can also be obtained.

◆ **Specular microscopy**

This provides information about the density of endothelial cells (cells per mm²), and the shape (percent hexagonality) and uniformity of the cell population. The terms polymegathism (variability in cell size) and pleomorphism (the lack of uniformity of the cell shape) are often used when describing the specular image. Although specular microscopes can image both central and peripheral areas, unless specifically stated, measurements are of the central and pupillary regions. Because this is a fairly large area, from 28 to 50 mm², some comment should be made about the number of random fields or percentage of the endothelial surface examined. A study showed that sampling greater than 20% of the surface was necessary to provide an accurate representation of the full endothelial surface.³⁶

Specular microscopy is of greatest value when it is combined with pachymetry and slit-lamp biomicroscopy examination. It can be very helpful, though, when following a patient over time; progressive loss of cells, as in a patient with vitreous touch syndrome, may be a finding that pushes the patient towards surgery, where stabilization of the cell count would encourage a conservative approach. When diffuse, confluent guttae are present on slit-lamp biomicroscopic examination, specular microscopy rarely provides any valuable information because it is difficult to image the endothelial cells.

◆ **Confocal microscopy**

This noninvasive diagnostic technique allows in vivo, microscopic imaging of the layers of the cornea. Endothelial cells are characterized by a relatively regular hexagonal hyper-reflective shape surrounded by hyporeflective borders. Endothelial cell counts with confocal and specular microscopy are comparable.³⁷ Whereas specular microscopy is often ineffective at visualizing the endothelium in cases of corneal edema, confocal microscopy is capable of imaging the endothelium in cases of moderate corneal edema. This is particularly helpful when assessing unilateral cases of corneal edema. Iridocorneal endothelial (ICE) syndrome, epithelial and fibrous ingrowth, and PPCD have distinctive confocal appearances (of the posterior surface) that may be very helpful in identifying an underlying cause for the decompensation preoperatively. Additionally, stromal opacities and certain

infectious organisms, such as fungal hyphae and *Acanthamoeba* cysts, have a distinct appearance on these images that can help guide diagnosis and treatment.

- ◆ Anterior segment optical coherence tomography

Anterior segment OCT provides high-definition, cross-sectional images of the cornea, angle, and anterior chamber. Two types of instruments are presently in use: spectral domain and time domain. Spectral domain instruments have higher resolution but less depth of field. Time domain instruments, which use a longer wavelength of light (1310 nm), are capable of imaging the ciliary body as well, though not with the same clarity as ultrasound biomicroscopy (UBM). Measurement tools to document and follow changes in the corneal thickness, anterior chamber angle configuration, and anterior chamber depth are standard with all models. Pachymetry mapping is available. Anterior segment OCT can be used to follow changes in corneal thickness; however, its greatest value lies in its ability to image deep and retrocorneal structures. The depth of a corneal scar or deposits in the cornea can be analyzed on the images. Corneal edema or scarring may be hiding a detached Descemet membrane or a retrocorneal membrane, which can be visualized using Anterior segment OCT. A large Descemet break and central stromal cleft may exist in cases of corneal edema associated with keratoconic hydrops or trauma. Anterior segment OCT can also guide endothelial keratoplasty management in the immediate postoperative period. Images can help determine areas of poor donor tissue adherence.

- ◆ Ultrasound biomicroscopy

Ultrasound is capable of providing real-time cross-sectional images of the anterior and posterior segment. Its advantage over light-emitting imaging devices is that it is not impeded by opacities of the cornea, anterior segment, or vitreous. Conventional ultrasound uses a frequency of 10 MHz. Ultrasound biomicroscopy uses much higher frequencies (35 to 80 MHz) that result in a significant improvement in resolution. Ultrasound biomicroscopy systems are suitable for imaging virtually all anterior segment anatomy and pathology, including the cornea, iridocorneal angle, anterior chamber, iris, ciliary body, and lens. The imaging of a ruptured or dislocated Descemet membrane, retrocorneal membranes, and iridocorneal and lenticulocorneal adhesions help to determine the root causes of an edematous or opaque cornea and aid in surgical planning. It is particularly helpful in congenital and traumatic cases. Additionally, it can locate small anterior segment foreign

bodies that are difficult to detect by slit-lamp biomicroscopy examination or AS-OCT.

MANAGEMENT

General Treatment Goals

The primary therapeutic goal is to control the underlying cause of the corneal edema or opacity (when active or progressive) and enhance the patient's quality of life by improving visual acuity and maximizing comfort. The ophthalmologist should provide the patient with an understanding of available treatment alternatives, balanced expectations of the amount of visual function that can realistically be preserved or recovered, and the risks of potential complications. The requirements for visual function will vary from individual to individual, and these needs must be considered when discussing treatment alternatives. Treatment may be optical, medical, surgical, or a combination, depending on the etiology, nature and severity of the opacity as well as the needs, desires, and health status of the patient.

In most cases, treatment starts with medical management. When these measures are insufficient, surgery may be considered. While improving visual acuity and maximizing comfort are the most frequent reasons to recommend surgery, improving visualization of the posterior segment, reducing the risk of infection, and improving a disfiguring condition may also be reasons that lead to surgery.

Medical Management of Corneal Edema

Chronic corneal edema is most commonly related to endothelial dysfunction, elevated IOP, and/or intraocular inflammation.³⁸ A careful ophthalmologic examination will often assist in determining which of these causes is most likely. The hyperosmotic effect of topical sodium chloride 5% drops or ointment or the use of a hairdryer (for either primary or secondary edema) are commonly suggested temporizing routines. Their ability to improve vision or reduce symptoms, however, is often limited. They should be discontinued after a number of weeks if no benefit is noted. Topical antibiotics may be necessary to reduce the risk of secondary infection when bullae rupture.

Lowering of the IOP is helpful when it is elevated or at the upper end of the normal range. Although any hypotensive agent may be beneficial in theory, prostaglandin analogues have a potentially inflammatory character and should be avoided in patients for whom inflammation is a possible contributing factor.^{39,40} When endothelial dysfunction is a possible contributing factor, topical carbonic anhydrase inhibitors

should not be first line therapy because of their potential to interfere with the endothelial pump.^{41,42} When inflammation is present, it should be controlled by adding a topical corticosteroid once possible infection has been ruled out or controlled.

Microcystic or bullous epithelial disease may produce discomfort or pain, necessitating the placement of a bandage contact lens to alleviate these symptoms. Although many different lenses may be used, thin lenses with high water content and high oxygen diffusion coefficients (i.e., Dk levels) are thought to be most advantageous.⁴³ Generally, a flat lens that will have some movement on blinking is desirable. If there is concomitant dry eye disease, preservative-free artificial tears may be necessary to facilitate sufficient movement of the lens. When a bandage contact lens is used, a topical prophylactic broad-spectrum antibiotic should be considered to decrease the risk of secondary infection.

Patients should be informed of the risk of infectious keratitis when wearing a bandage contact lens and the need to contact their treating ophthalmologist if redness, pain, or increased photophobia develops. One study suggested an increased risk of infectious keratitis associated with use of bandage contact lenses, and antibiotics may not protect against the risk of infection.⁴⁴ Ideally, bandage contact lenses should be used for a limited treatment period; however, in many cases, longer-term use may be required. In this situation, periodic exchange of the lens is advised. Regular follow-up is necessary under these circumstances to reassess the lens, look for evidence of a change in the patient's ocular status, and re-emphasize the need for vigilance on the part of the patient.⁴⁴

For cases of acute hydrops, supportive management should be initiated to reduce inflammation and/or pain. Patients can be started on topical corticosteroids, cycloplegic agents, hyperosmotic drops and ointments, and/or topical antibiotics while monitoring for improvement and resolution of edema. In the case of an acute perforation, surgical intervention may be necessary.

Surgical Management of Corneal Edema

Patients with corneal edema and persistent discomfort, but limited or no visual potential, are generally better candidates for a conjunctival flap, amniotic membrane transplant, or one of a number of scarification procedures. Occasionally, patients with good vision will opt for one of these treatments when extenuating circumstances affecting general health or follow-up care/transportation are an issue.

Patients with longstanding bullous keratopathy often develop a layer of subepithelial scar tissue that is associated with reduced bullae production and reduced pain.

Intentional scarification of the corneal surface to recreate this effect has been a longstanding surgical approach when improved vision was not the principal concern. Anterior stromal puncture with an electrocautery⁴⁵ or needle⁴⁶ has been found to be effective. Intentional scarification requires caution, because overtreatment can lead to necrosis and corneal melt.⁴⁷

There are numerous keratectomy and keratoplasty procedures that can be considered for treating persistent corneal edema. Acronyms abound and are often confusing because of their similarities. Good examples are anterior lamellar keratectomy (ALK), automated lamellar therapeutic keratoplasty (ALTK), femtosecond laser-assisted anterior lamellar keratoplasty (FALK), and femtosecond laser astigmatic keratotomy (FLAK). Table 2 lists many of the more common keratectomy and keratoplasty procedures.

TABLE 2 CONTEMPORARY KERATECTOMY AND KERATOPLASTY PROCEDURES

Acronym	Procedure
ALK (ALTK)	Anterior lamellar keratoplasty (therapeutic)
DALK	Deep anterior lamellar keratoplasty
DLEK	Deep lamellar endothelial keratoplasty
DMEK	Descemet membrane endothelial keratoplasty
DSEK (DSAEK)	Descemet stripping endothelial keratoplasty (automated)
EK	Endothelial keratoplasty
FALK	Femtosecond anterior lamellar keratoplasty
FLAK/FLEK	Femtosecond laser assisted (enabled) keratoplasty
PD-DALK	Pre-descemet deep anterior lamellar keratoplasty
PKP/PK	Penetrating keratoplasty
PRK	Photorefractive keratectomy
PTK	Phototherapeutic keratectomy
SK	Superficial keratectomy

Phototherapeutic Keratectomy

Excimer phototherapeutic keratectomy (PTK) with ablations to a depth of 100 μm or greater has been used alone⁴⁸⁻⁵⁰ or in combination with self-retaining amniotic membrane grafts^{51,52} to reduce pain and promote surface stability. Pain relief is purportedly achieved by ablation of the sub-basal nerve plexis.⁵³ A less involved technique for achieving the same result is an annular keratotomy created by corneal trephination to a mid-stromal depth.⁵⁴ Phototherapeutic keratectomy for corneal edema will not produce long-term visual rehabilitation.

Conjunctival Flap

Rapid corneal healing, ocular comfort, and reduction in ocular inflammation can be achieved with a conjunctival flap.^{55,56} Conjunctival flaps are used to allow an eye to quiet before more definitive therapy is performed. Conversely, full conjunctival flaps (Gundersen) may be used as definitive surgery when additional reconstructive surgery is not anticipated.⁵⁵

Amniotic Membrane Tissue Transplantation

An improved understanding of the importance of preserving stem cells has led to the use of amniotic membrane.⁵⁷⁻⁵⁹ Placement of an amniotic membrane can be performed using an “inlay”⁶⁰ or “overlay”⁶¹ technique. In the inlay method, the amniotic membrane acts as a scaffold for epithelial cells that migrate onto the membrane from the surrounding region. It is hoped that some of the membrane will persist after healing to create a barrier effect and prevent new bullae from forming. In the overlay method, the amniotic membrane is applied as a patch and sutured to the conjunctival surface.⁶¹ Here, it functions as a biologic contact lens, and epithelial healing takes place underneath the layer of amniotic membrane, which then resorbs. Self-retaining amniotic membranes are available for use under a therapeutic lens or fixated to a scleral ring. These are “onlay” in nature and require no suturing, making them convenient for use in the office setting.

Corneal Transplantation

Corneal transplantation, either full-thickness penetrating keratoplasty (PK) or as a lamellar procedure (Descemet stripping automated endothelial keratoplasty [DSAEK] or Descemet membrane endothelial keratoplasty [DMEK]), is the most common therapeutic option chosen by patients who have corneal edema and reduced vision or significant pain due to bullous keratopathy. Factors that determine whether full-thickness or lamellar surgery are to be recommended include the presence and extent of subepithelial or stromal scarring, concerns about the impact of ocular surface disease on epithelial healing and stability, and the extent of any reconstructive intraocular surgery that might be necessary at the time of surgery. Prior posterior vitrectomy, aphakia, filtering or shunt surgery for glaucoma, extensive posterior synechiae, and a shallow anterior chamber are findings that impact the success of endothelial keratoplasty (EK) and have to be taken into consideration as well. The quicker vision rehabilitation and lower risk of

EK may in some circumstances outweigh the greater risk and slower visual rehabilitation of penetrating keratoplasty.

Penetrating Keratoplasty

Graft failures in PK generally occur as a consequence of rejection reactions within the first few years and, as a consequence of endothelial failure, during the later follow-up period. Although primary donor failure in EK is greater due to increased donor manipulation, recent data suggest that overall endothelial loss after the initial learning curve is comparable between DSAEK and DMEK.^{62,63} The problem of dislocation of the graft is a unique complication of EK surgery and is frequently associated with added tissue trauma owing to the efforts of the surgeon to reposition or reattach the tissue.

The differences in the rejection rates between procedures may be due to the introduction of less antigenic tissue (specifically, dendritic cells, which are generally found in the superficial stroma, and donor epithelium),⁶⁴ and because loose sutures, a recognized risk factor for rejections, are not an issue with EK.⁶⁵ Data from the Swedish Corneal Transplant Registry disclosed a rejection rate of 13% for penetrating keratoplasties in patients with Fuchs dystrophy and pseudophakic bullous keratopathy (PBK).^{66,67} This is similar to a study⁶⁸ that reported on a group of DSAEK patients who had rejection rates of 6.0%, 14.0%, and 22.0% at 1, 2, and 3 years, respectively. Similar values of 7.6% at 1 year and 12.0% at 2 years were reported in a different study.⁶⁹ Two studies that specifically compared the results of PK and DSAEK in Fuchs and PBK showed no statistically significant difference between the two groups with regard to rejection rates.^{70,71} However, recent reports in large cohorts show a significantly decreased risk of rejection in DMEK compared with both PK and DSAEK.⁷²

Graft survival for both PK and DSAEK at 5 years for Fuchs dystrophy and PBK is 95% and 73%, respectively.^{73,74} Endothelial decompensation, with or without a prior rejection episode, is the leading cause of graft failure for both. Other causes of PK graft failure such as traumatic wound rupture and ocular surface complications are not seen with EK.^{75,76} One often underappreciated advantage of EK is the decreased incidence of delayed surface healing and postoperative surface irregularity in patients with ocular surface disease, specifically dry eye and blepharitis. These factors significantly influence the speed of visual recovery and visual quality of many patients. Regrafting a PK that has developed endothelial decompensation using a DSAEK or DMEK benefits similarly and is being

considered with greater frequency. Interface opacities (e.g., epithelial ingrowth) and wrinkling of the donor button, with resulting reduction in correctable distance visual acuity, are causes of graft failure that are unique to EK and may lead to regrafting.

The most common problems following PK are ametropia and irregular astigmatism. The average postoperative astigmatism following PK was 4 to 6 diopters (D).⁷⁷⁻⁸⁰ The problem is similar in both phakic and pseudophakic cases. This compares with 1.50 D of total cylinder for DSAEK, where the surgically induced portion ranges from 0.40 to 0.60 D.⁸¹ Induced hyperopia following DSAEK, resulting from the donor lenticule being thicker in the periphery, averages 1.10 D with a range of 0.70 to 1.50 D.^{82,83} The more predictable optical result in DSAEK (e.g., postoperative spherical equivalent, astigmatism) is helpful for obtaining accurate IOL calculations for combined transplant/cataract procedures and for restoring or adjusting the target refraction in pseudophakic transplant eyes. The overall hyperopic refractive shift with DMEK is minimal, and individual adjustments in IOL power create less variance and decrease range of error. Short-term results for different surgical techniques for corneal edema are included in Table 3.

Corneal Edema and Opacification PPP

TABLE 3 COMPARISON OF SHORT-TERM RESULTS FOR DIFFERENT SURGICAL TECHNIQUES FOR CORNEAL EDEMA (FUCHS AND PSEUDOPHAKIC BULLOUS KERATOPHY)

	PK	DSAEK	DMEK
Dislocation rate	0.0%	14.5% ⁸¹ –15% ⁸⁴	5.9%–27.4% ^{85,86}
Wound dehiscence	1.3%–5.8% ^{76,87,88}		
Donor failure within 60 days	0.3% ⁸⁹	0%–29.0%; mean 5.0% ^{81,90}	2.2%–8.0%, ⁹⁰⁻⁹²
Rejection rate at:			
1 yr	17.0% ⁹³	2.0%–9.0% ^{62,93}	0%–6.0% ^{91,93}
2 yrs	9.7%–13.0% ^{66,67}	12.0%–14.0% ^{68,71}	5.6%–6.4% ^{63,72}
5 yrs	22.2% ⁸⁹	22.0%	
Graft failure rate at 5 yrs	5.0% for Fuchs/ 27.0% for PBK ⁷⁴	5.0% for Fuchs/ 24.0% for PBK ⁷⁴	0–12.5% ^{63,94}
BSCVA:			
% 20/40 or better at 1 yr	65.0%–84.0% with selective suture removal ⁹⁵	38.0%–90.0% ⁸¹	94.0% at 6 mos ⁹⁶ 97.0% 20/30 or better at 1 yr ⁹⁷
% 20/20 or better			37.6%–85% 20/25 or better ⁶³ 17%–67% ⁶³
Time to BCVA	6–12 mos with selective suture removal ⁹⁸	NA	2/3 stable by 3 mos ⁹⁶
Mean keratometric cylinder:			
sutures out	4.40±2.80 D		
at 2 yrs	3.70±3.20 D ⁹⁹	0.40–0.60 D induced; mean 0.10 D ⁹⁹	+0.40 D hyperopic shift, ⁹⁹ no change ⁹¹
with sutures in at 1 yr	2.50 D ⁹⁵		
Mean spherical equivalent change	2.80±2.10 D ¹⁰⁰	+1.10 D induced hyperopia ^{81,93}	+0.24 to +0.32 D ^{97,101}
Endothelial cell loss:			
1 yr	9.0%–19.0% Fuchs† 34.0% Fuchs/PBK ^{89,102}	37.0%, ⁷⁴ 40% ⁸⁴	32.0±20.0%, 34.0% ^{91,96} 36.0%, ^{97,103} 25%–57% ⁶³
2 yrs	27.0%–42.0% Fuchs, 54.0% Fuchs/PBK ^{89,102}	44.0% ⁷⁴	
5 yrs	69.0%–75.0% Fuchs, 61.0% Fuchs/PBK ^{89,102}	53.0% ⁷⁴	42%–48% ⁹⁴

BCVA = best-corrected visual acuity; BSCVA = best spectacle-corrected visual acuity; D = diopter; DLEK = deep lamellar endothelial keratoplasty; DMEK = Descemet membrane endothelial keratoplasty; DSAEK = Descemet stripping automated endothelial keratoplasty; NA = data not available; PBK = pseudophakic bullous keratopathy; PK = penetrating keratoplasty.

* Only includes dislocations that influenced the result; edge dislocation or tag not counted. If all dislocations are counted = 8.0%–24.0%.

† Range – two donor age groups.

Endothelial Keratoplasty

The development of EK has profoundly influenced the surgical management of corneal edema.¹⁰⁴ Prior to 2000, virtually all corneal transplant candidates with decompensated corneas underwent PK. That is in contrast to the 2016 Eye Bank Association of America's Statistical Report, which indicates that approximately 44% of keratoplasty done in the United States was EK versus 38% for PK.

Furthermore, the report indicates that 93% of patients with Fuchs dystrophy were treated with EK.¹⁰⁵ This is a technique that is still improving as techniques and graft handling evolves. It began as deep (posterior) lamellar endothelial keratoplasty (DLEK), which required the removal and replacement of a posterior stromal/Descemet membrane lenticule. The optical imperfections from the stroma to stroma interface and dissection difficulties quickly transitioned EK surgery to DSEK or DSAEK. Both DSEK and DSAEK involve the removal of the recipient Descemet membrane and its replacement with a thin donor lenticule that includes posterior stroma and Descemet membrane. The DSEK donor tissue is usually manually prepared by the surgeon, whereas DSAEK donor tissue is precut by a microkeratome. In effect, the DSAEK technique adds a posterior donor lenticule that acts as a net negative lens, causing a hyperopic shift to the optics of the eye. This shift should be taken into consideration at the time of cataract surgery whenever possible. Finally, the most recent transition to DMEK for cases of mild to moderate corneal edema is a direct exchange of the diseased Descemet membrane/endothelium with a healthy donor Descemet membrane/endothelium. Despite the early challenges of a steep surgical learning curve, it is now a well-accepted EK procedure with decreased long-term rejection risk,⁷² more rapid visual recovery, and improved optical outcomes.¹⁰⁶ Cataract extraction is often performed prior to or at the same time as EK when significant cataract changes exist. For DMEK, minimal IOL-power adjustment is required as it is a replacement (not additional) surgery. There is some evidence that there is minimal change to corneal astigmatism.¹⁰⁷

The broad acceptance of EK is due to the rapid visual recovery, significantly greater optical predictability (both astigmatic and refractive), smaller and more stable wounds, and decreased risk of graft rejection compared to with PK.^{68,69,81}

The intraoperative and postoperative surgical complications of EK are quite different from those seen with PK. Suture and wound-related complications such as suture erosion and infection, vascularization, and spontaneous or traumatic

wound dehiscence encountered in PK patients are rare problems with EK procedures.⁸¹ On the other hand, graft decentration or dislocation with the need to recenter or rebubble in the office or operating room, acute angle-closure glaucoma and lamellar interface problems may occur with EK.

For DMEK surgery, the addition of an “S” stamp to help with graft orientation and the use of SF₆ gas has significantly reduced the rate of iatrogenic primary graft failures and rebubbling rates.^{108,109} These advances have made DMEK a leading surgical choice for standard endothelial failure with good anterior chamber visibility.

Descemet stripping automated endothelial keratoplasty surgery continues to be a leading surgical choice for eyes with decreased anterior chamber visibility or complex situations such as previous glaucoma surgery or eyes with iris defects. Ultrathin DSAEK tissue (defined as <100 μm thick) has shown some favor in terms of visual recovery compared to standard DSAEK, although complication rates and refractive outcomes are similar.⁸⁴

Donor preparation of tissue for EK surgery is performed mostly by eye banks now. Precutting DSAEK tissue to the surgeon’s specified thickness is routinely done. It can be more difficult to prepare DMEK tissue and the result is slightly more tissue wastage. However, in the hands of a skilled eye bank technician this is negligible.

Finally, primary descemetorhexis procedure with or without the use of a topical Rho kinase inhibitor to facilitate endothelial health has been successfully performed.^{110,111} This procedure involves the removal of a 4 to 5 mm central portion of Descemet membrane and diseased endothelium without transplantation of donor tissue. The potential for future ex vivo expansion of injectable endothelial cells is also under investigation.¹¹²

Medical Management of Corneal Opacification

Treatment of a corneal opacity can be divided into two phases: the management of the principal, initiating process (i.e., infection, trauma) and the management of the resulting problems (i.e., surface erosions and irregularity, scarring, thinning, and vascularization). This PPP is focused on the second phase.

Many corneal opacities start as persistent, nonhealing epithelial defects that opacify as a result of infection, inflammation, tissue breakdown, and/or scarring. Conventional treatment of an epithelial defect involves the use of an antibiotic drop or ointment that

will protect against secondary bacterial infection. The choice of antibiotic should take into account the normal flora of the skin and conjunctival flora, the patient's immune status, and any underlying medical problems (i.e., diabetes, Parkinsonism).

Adequate blinking during waking hours and complete lid closure when sleeping are very important for ocular surface healing and need to be assessed in any situation where a defect persists. A temporary tarsorrhaphy with botulinum toxin, or suture can be helpful when blinking or lid closure is inadequate. Pressure patching used to be standard treatment for abrasions and erosions; however, a recent study found that this does not positively impact comfort or the speed of healing.¹¹³ [I+, Good, Discretionary] A bandage contact lens or amniotic membrane may be very helpful in cases of delayed healing.

The fact that many ocular surface defects are unresponsive to the above measures has spawned a search for alternative agents to promote surface healing. Oral doxycycline,¹¹⁴ topical acetylcystine, and medroxyprogesterone have been shown to inhibit matrix metalloproteinases and have been investigated, with varying results, as ways to manage persistent epithelial and stromal defects. In vivo benefits are hard to assess, particularly in a structured, double-masked setting. Autologous serum,¹¹⁵ cord blood tears,¹¹⁶ and platelet-rich plasma¹¹⁷ have demonstrated beneficial effects for persistent epithelial defects. The need to have these products prepared by a blood and eye bank and/or compounding pharmacy limits their availability. Nerve growth factor,^{118,119} substance P and insulin-like growth factor-1,¹²⁰ fibronectin,¹²¹ and thymosin beta 4¹²² have all shown some benefit in selected cases but remain investigational.

Amniotic membranes, either as an onlay⁶¹ protective flap or as an inlay⁶⁰ tissue substitute, are thought to promote healing by their release of various anti-inflammatory, anti-angiogenic, and prohealing mediators.¹²³⁻¹²⁵ The introduction of these membranes, attached to scleral rings¹²⁶ and as wafers that can be placed under a contact lens, has expanded their flexibility and allows for in-office utilization.

Progressive thinning of the cornea or a small perforation usually requires structural support with the application of a tissue adhesive. A small area of marked thinning or an early descemetocele may be coated with a thin layer of adhesive (e.g., cyanoacrylate), which may remain in place for 6 weeks or longer if applied to a clean and compact base. If located peripherally, this may be definitive treatment; if located centrally or paracentrally, the adhesive will facilitate the nonemergent repair of the defect. Leaking descemetocelles may sometimes require the injection of an air bubble into the anterior chamber to halt the leakage temporarily while glue is applied. The base of a defect

needs to be dry for the adhesive to adhere properly. Tissue adhesive will work best when the area of impending perforation is small and at the bottom of a crater and not with a ballooning descemetocoele. Various techniques have been advocated for the application of tissue glue, including the use of a 30-gauge needle, the wooden end of a cotton applicator, or a micropipette.¹²⁷ Application of the least amount of glue that will seal or support the defect should be attempted. While tissue adhesive has not been approved by the US Food and Drug Administration (FDA) for use on the eye, it has been widely used internationally for many years. It is advisable to use a sterile product to reduce the risk of a secondary infection. Fibrin glue should not be used with corneal perforations or descemetocoeles because it is biodegraded rapidly before healing can occur. Bandage contact lenses are applied to prevent dislocation of the glue and provide comfort.

Topical corticosteroids are often used to reduce intraocular as well as corneal inflammation. Intraocular pressure and cataract formation should be monitored with long-term topical corticosteroid use. Their role in limiting corneal scar tissue development after an acute or subacute process has resolved has not been well established, however.^{128,129} A number of studies have looked at their effect on healing and visual acuity when used in the treatment of acute corneal ulcers and found no benefit to their use.^{130,131} Agents that have been used to reduce the development of scar tissue following glaucoma and refractive surgery (mitomycin-C,¹³² 5-fluorouracil,¹³⁰ tacrolimus,¹²⁸ octreotide,¹³¹ and pirfenidone¹³³) have been associated with epithelial surface toxicity at the commonly used doses¹³⁴ or have not been evaluated as to their anti-scarring effect in corneal disease.

Reduced vision in cases of corneal opacification is often related to surface irregularity (easily demonstrated with the keratometer) in addition to the opacity itself. An RGP lens (hybrid or scleral lens when greater stability is needed) will often improve the vision when surface irregularity is a major factor and may obviate the need for more invasive procedures. A trial fitting with spectacle overcorrection (to demonstrate potential improvement) can be performed easily in the office with a small set of RGP lenses.

Painted contact lenses and scleral shells are also available to hide an opacity when the visual potential is poor. The greater thickness of the scleral shell makes it an ideal choice when there is reduced orbital volume or phthisis bulbi. Painted contact lenses are available with a clear pupillary zone and opaque periphery for patients with peripheral opacities.

Surgical Management of Corneal Opacification

The surgical strategy for managing corneal opacities depends on which tissue layer(s) is involved. In most cases, this is determined during the slit-lamp biomicroscopy examination, however, UBM and AS-OCT can be extremely valuable in some cases. Superficial keratectomy may be indicated for the removal of superficial deposits, lamellar keratoplasty (LK) for deeper deposits, and PK for even deeper, multilevel opacities. Table 4 highlights the relationship between depth of disease and surgical alternatives.

TABLE 4 LAYER-BASED APPROACH TO THE SURGICAL MANAGEMENT OF CORNEAL OPACITIES

Layer of Pathology	Representative Disease	ED	SK	PTK	ALK	DALK	EK	PK
Epithelium	Redundant, irregular epithelium	•						
Subepithelial	Epithelial basement membrane dystrophy	•						
Subepithelial	Salzmann nodular degeneration	•	•					
Bowman	Band keratopathy	•	•	•				
Bowman	Reis-Bücklers dystrophy		•	•	•	•		
Anterior – mid-stroma	Granular dystrophy		•	•	•	•		•
Mid-posterior stroma	Scarring				•	•		•
Endothelium	Fuchs dystrophy						•	•

ALK = anterior lamellar keratectomy; DALK = deep anterior lamellar keratoplasty; ED = epithelial debridement; EK = endothelial keratoplasty; PK = penetrating keratoplasty; PTK = phototherapeutic keratectomy; SK = superficial keratectomy

Epithelial Debridement

Epithelial debridement is most helpful with lesions anterior to Bowman layer. Anterior basement membrane dystrophy, recurrent erosions, and Salzmann nodular degeneration are some of the conditions wherein debridement is performed most frequently. A lid speculum and a round or curved microblade are the only equipment necessary. An office slit-lamp biomicroscopy examination is often the easiest setting for performing debridement if the patient is cooperative, because the narrow slit beam makes it easier to judge depth. An operating microscope in a minor surgical suite or operating room can also be used if the patient is uncooperative or if other procedures are to be performed at the same time. In epithelial basement membrane dystrophy, the bulk of the epithelium tends to be loose and easily removed. Care needs to be taken to remove multilayered basement membrane, which is often present. Epithelial debridement can be performed in conjunction with mitomycin and/or PTK (as discussed below). Following

epithelial debridement, a bandage contact lens and prophylactic topical antibiotics are often instilled.

Use of Mitomycin-C

Mitomycin-C for subepithelial, Bowman layer, and anterior stromal scarring may be helpful in selected cases where recurrence is a concern.^{135,136} Definitive criteria for use of mitomycin-C, as well as the most effective method, dose and period of application, have yet to be established for corneal disorders. The most frequently reported dose of mitomycin-C used is 0.02% (0.2 mg/mL) applied using a wet cellulose disk, making sure that the mitomycin-C does not spread beyond the treatment area. Treatment time roughly divides into two groups: 12 to 20 seconds when used as prophylaxis against the development of postkeratectomy haze or scarring, and 30 to 120 seconds when used to prevent the recurrence of scarring. Care must be taken to ensure that the proper dose of mitomycin is formulated by the pharmacy and that close attention is paid to the exposure time. Mitomycin-C may cause generalized loss of keratocytes¹³⁷ and endothelial toxicity, and can be a risk for limbal stem cell toxicity or corneal melt if used in excess. Copious irrigation of the surface and the surrounding area with saline or a balanced salt solution afterwards is important to reduce the risk of progressive toxicity at the surgical site or adjacent limbus. The use of mitomycin-C is based on the evaluation by the ophthalmologist and the consideration of potential advantages and disadvantages in each case. Mitomycin-C has not been FDA approved for use in the eye, and this should be explained to the patient, along with the risks and benefits.

Management of Anterior Stromal Opacities

Anterior corneal lesions that extend beyond Bowman layer into the anterior and mid-stroma require more extensive treatment than described above. Measurements of the size and depth of the corneal opacity obtained with AS-OCT, UBM, or confocal microscope may be very helpful in determining which management approach is most suitable.

Superficial Keratectomy

Once the epithelium is removed in Salzmann nodular degeneration, the underlying Salzmann nodule/subepithelial fibrosis also needs to be excised. Often a plane between the opacity and underlying Bowman layer can be found, resulting in a relatively smooth corneal surface. When a smooth plane cannot be fashioned, an LK procedure may be required to achieve the best result.

Lamellar keratoplasty and superficial LK or ALK are techniques that have been utilized since the early 1900s and until the early 1970s were the prevailing surgical approach to manage diseases that did not affect the endothelium.¹³⁸ “Freehand” lamellar keratectomies, regardless of the depth, have the advantage of requiring minimal equipment (a microblade, lamellar dissector, or spatula). However, the difficulty in achieving a uniform or smooth interface and the associated poor visual results have limited its utility.¹³⁹

An ALK performed using a microkeratome or femtosecond laser has the advantage of achieving a smoother bed than most freehand dissections can achieve. The epithelium can be allowed to cover the stromal bed or an onlay lamellar transplant can be applied.¹⁴⁰ The depth of the microkeratome (base plates range from 120–350 μm) or femtosecond dissection and the thickness of the resulting bed determine whether tissue replacement is necessary. Superficial corneal flaps, created using either system, combined with excimer laser ablation to the stromal bed, can be performed to remove an anterior-to-mid-stromal opacity either partially or totally when the overlying stroma is clear.¹⁴¹⁻¹⁴³ Stromal haze, which can be reduced using mitomycin-C, and hyperopia are post-treatment issues that need to be taken into account when planning treatment.

In cases of simple microkeratome/femtosecond laser keratectomy or combined procedures (with PTK), the visual results (i.e., final BCVA [best-corrected visual acuity] and contrast sensitivity) show significant improvement.¹⁴⁴ Both measurements are influenced by the amount of postoperative surface and interface irregularity, residual stromal haze, or scar tissue.^{145,146} In most cases, uncorrected visual acuity (UCVA) is not significantly improved at 6 months.^{135,136} Best-corrected visual acuity, however, is significantly improved at 2-, 6-, and 12-month time points in cases of mechanical/femtosecond flaps combined with PTK.^{135,136} The aberrometric data demonstrate that improvement of visual acuity is correlated with an improvement of corneal transparency, corneal regularity, and optical quality.¹³⁶

Excimer PTK is used in the management of superficial and anterior stromal opacities to improve epithelial stability or visual acuity. Common conditions that can be treated using this modality are epithelial basement membrane dystrophy,¹⁴⁷ bullous keratopathy,⁵³ residual subepithelial haze or scarring following removal of band keratopathy or Salzmann nodular degeneration,¹⁴⁸⁻¹⁵⁰ anterior stromal scarring, Reis-Bücklers,¹⁵¹ and granular and lattice dystrophies.¹⁵² Multiple

treatments are possible with recurrent disease and can be combined with refractive treatment to reduce ametropia or astigmatism.¹⁵³ Phototherapeutic keratectomy treatment is most beneficial when corneal opacities are limited to the anterior 10% to 15% of stromal thickness. Treatment to deeper levels is associated with higher order aberrations, irregular astigmatism, and a significant hyperopic shift unless treatment modifications are included. Visual rehabilitation tends to be fairly rapid, and most patients achieve improvement in BCVA when the underlying reason for treatment is corneal opacification. In some cases (e.g., granular and lattice dystrophies), it may be possible to avoid or at least defer LK or PK.

Recurrence of the underlying disease process, posttreatment surface irregularity, and hyperopia are the most frequent problems seen with PTK. The application of mitomycin-C at the time of the initial or follow-up PTK treatment has been investigated as a means of diminishing recurrent scar tissue or stromal deposits. Its use on a circular sponge applied to the corneal stroma after laser treatment has shown some benefit in haze and opacity recurrence;^{154,155} however, caution needs to be taken as stromal melt and ocular surface toxicity can occur. Copious irrigation of the surface and the surrounding area with saline or a balanced salt solution afterwards is important to reduce the risk of progressive toxicity at the surgical site (specifically endothelial toxicity) or adjacent limbus.

The excimer laser removes tissue equally from raised and depressed areas. As a result, treatment of an irregular surface etches the surface topography into the underlying layers. To prevent this and facilitate creation of a smooth surface, a masking agent (often methylcellulose or sodium hyaluronate) is used. This fills the valleys so that the peaks can be ablated first. Dense scar tissue and calcium require more energy for ablation than normal tissue. Masking of normal tissue adjacent to a dense scar or calcium is therefore necessary to prevent the development of a surrounding area of depression.¹⁵⁶

Greater depth of treatment has been associated with post-PTK haze as well as a hyperopic shift.¹⁵⁷ The flattening effect that causes this can be reduced by treating along the outer edge of the ablation zone with small spot ablations¹⁵⁸ or by using a refractive setting.^{144,147}

Table 5 summarizes some of the differences between the superficial and anterior lamellar keratectomy techniques.

TABLE 5 COMPARISON OF TECHNIQUES USED IN SUPERFICIAL AND ANTERIOR LAMELLAR KERATECTOMY

	Freehand	Microkeratome	PTK	Femtosecond
Depth of dissection	Flexible but less accurate	120–350 μm	Flexible but less accurate due to uneven ablation	90–280 μm
Flap parameters	Flexible	Limited	NA	Flexible
Flap complications	Occasional	Occasional	NA	Rare
Bed smoothness	Worst	Better	Variable	Best

NA = not applicable; PTK = phototherapeutic keratectomy

Management of Band Keratopathy

Use of disodium EDTA^{159,160} to facilitate the removal of a calcific band keratopathy can be very helpful. The goal of treatment is to remove the calcium opacities in the pupil and to restore comfort and vision. When the calcium forms thick flake or plaque-like excrescences, they can be removed with forceps and scraping, otherwise removal of the overlying epithelium is all that is necessary prior to EDTA treatment.¹³⁹ A cellulose sponge or a sterile cotton applicator soaked in a 3% to 4% disodium EDTA solution can be rubbed against any residual calcium until dissolution occurs. Alternatively, direct application of EDTA drops to the exposed calcium band, the use of a well filled with EDTA, or the application of an EDTA-soaked cellulose disc directly over the exposed calcium may result in dissolution of the band keratopathy. Treatment time with EDTA may vary depending on the density of the calcium and the approach used. This procedure can be performed in the clinic with debridement at the slit-lamp. Mild postoperative anterior stromal haze may occur. The mean time to healing may be delayed after EDTA chelation when compared with normal eyes that have a similar-sized corneal abrasion (5–7 days vs. 2–3 days), presumably due to alterations in the underlying corneal pathology.

Corneal Tattooing

Corneal tattooing has been used for centuries to treat cosmetically objectionable corneal leukomas. The original technique involved imbedding India ink or carbon particles in the anterior and mid-stroma using a process similar to corneal stromal puncture. Often, the procedure had to be repeated to achieve the desired distribution and density of pigment. Over time, the pigment tended to migrate from the puncture wounds and the procedure needed repeating. The most versatile techniques in use now involve the creation of a lamellar pocket or flap (by hand or

femtosecond laser) into/under which pigment is instilled. This technique is easily adapted to corneal opacity of almost any size and shape. The density and color distribution of the pigment can be varied according to the case. Densely pigmented, discretely edged tattoos often appear to be “stuck on” the surface of the cornea. This lack of depth is usually not a major problem when functional issues are the primary concern, but it needs to be kept in mind when cosmetic issues are dominant.

Keratoplasty

Removal and replacement of diseased layers of the cornea is necessary when managing corneal opacification or edema if significant tissue thickness is involved, or when the endothelium is compromised and unresponsive to conservative measures. Surgical and eye-banking advances have had a significant impact on the availability of donor tissue, the indications for surgery, the frequency with which keratoplasty is performed, and the procedure’s rate of success.

Corneal transplantation (keratoplasty) has been the mainstay of treatment for corneal opacities involving the mid and deep stroma. Since the late 1960s, full-thickness PK was the standard approach. Endothelial keratoplasty has supplanted PK as the procedure of choice in cases of endothelial failure when corneal scarring is minimal because patients achieve more rapid visual recovery. The dramatically reduced risk of postkeratoplasty astigmatism, suture-related infections, and traumatic wound rupture are further advantages of EK. The preferred technique continues to evolve. Within the realm of LK, further advances have enabled surgeons to perform anterior lamellar, deep lamellar, and endothelial lamellar procedures.

Lamellar

Anterior Lamellar Keratoplasty

When ALK results in sufficient tissue removal to thin the cornea and creates conditions that might lead to progressive ectasia (as may be seen for refractive procedures) or surface irregularity, tissue replacement is necessary. While optical and tectonic rehabilitation can be achieved with ALK, it has historically been viewed as a tectonic procedure because of difficulties controlling interface scarring, achieving a smooth dissection, and quality vision.

The advantages of ALK over PK include the absence of endothelial rejection, greater wound strength, and improved safety (since it is an extraocular

procedure). These advantages have stimulated efforts to produce a smoother recipient base and donor stromal surface, using improved manual, microkeratome, and femtosecond laser-dissection techniques. Numerous studies have demonstrated improvement in the quality of the interface with these techniques.^{161,162} Correspondingly, visual acuity improvements to 20/30 or 20/40 have been reported by numerous investigators using microkeratome-assisted ALK¹⁶¹ or FALK.¹⁶³⁻¹⁶⁶ In some cases, no sutures were used to secure the donor lenticules, resulting in reduced postkeratoplasty astigmatism.¹⁶⁴

Anterior Lamellar Therapeutic Keratoplasty

Partial-thickness defects related to melting disorders (e.g., central corneal ulcers, peripheral ulcerative keratitis, Terrien marginal degeneration) or peripheral ectasia (e.g., pellucid marginal degeneration, post-PK wound thinning) may need to be managed surgically if excessive thinning or descemetocoele formation develops. Central grafts are usually circular in shape, and the size is determined by the size of the defect and whether the graft's edge will impinge on the pupil. In the periphery, the pathology may be annular in nature and require a concentric donut or partial crescentic graft. These are technically more difficult, and although they are often done because of thinning and the secondary astigmatism that results from this, they are frequently associated with modest postoperative astigmatism. In some cases, a full-thickness patch or crescentic graft is needed. Donor tissue for ALTK procedures may be partial-thickness irradiated tissue, glycerin preserved tissue, or preserved tissue provided by an eye bank.¹⁶⁷⁻¹⁶⁹

Deep Anterior Lamellar Keratoplasty

Lamellar keratoplasty using DALK techniques can be considered for cases of mid to deep stromal scarring. The deep LK technique removes all or nearly all of the corneal stroma down to Descemet membrane. The benefits of DALK are that it preserves the host endothelial layer and reduces the long-term endothelial cell loss characteristic of PK. While stromal rejection reactions can occur in both DALK and PK, this risk is reduced since the host keratocytes replace the donor cells. The risk of endothelial rejection, however, is not an issue in DALK because this layer is preserved.^{163,170,171}

A variety of manual techniques exist to aid in the separation of the posterior stroma from Descemet membrane, including the Melles technique, the big-bubble technique, and variations on the big-bubble technique.^{20,172} The femtosecond-assisted big-bubble technique utilizes a femtosecond laser program to trephine the cornea, followed by big-bubble formation from air injection into the posterior

stroma and placement of a femtosecond laser-trephined cornea to complete the DALK.¹⁷³ Use of a customized trephination pattern, such as the “zigzag” pattern, combined with the big bubble DALK technique can improve wound integrity and healing.¹⁷⁴

Outcomes

Most of the comparative studies looking at DALK and PK relate to keratoconus; however, similar results and issues would be expected to apply to noninflammatory, nonvascularized and nonprogressive central corneal opacities as well. The studies comparing visual results of these procedures in keratoconus patients appear conflicting until they are viewed according to how much posterior stroma was left behind. Greater variation in the postoperative visual acuity and contrast sensitivity following DALK has been correlated to increased thickness of the residual recipient posterior stromal bed and donor-host interface reaction. When baring of Descemet membrane is achieved (termed predescemet [PD]-DALK), visual results are reported to be comparable with PK.^{163,175-181} Unfortunately, baring of Descemet membrane is not consistently achieved; successful baring has been reported in 47% to 82% of eyes, even in experienced hands.^{172,178,182,183} A residual bed of less than 20 μm is ideal for achieving similar visual results when compared with PK.¹⁷⁵ Conversion to a full-thickness PK may be required if there is perforation of the Descemet membrane. The need for conversion may be associated with the surgeon’s learning curve and may decrease with increased surgeon experience with the technique.^{163,182} Endothelial cell loss was significantly lower with DALK performed without Descemet membrane perforation when compared with full-thickness keratoplasty.¹⁸³⁻¹⁸⁷

Complications

Complications related to LK include suture-abscess formation, surface erosions, interface opacities, infectious keratitis, neovascularization, and stromal graft rejection and failure. Endothelial rejection, however, is not seen. Complications that are unique to DALK include rupture of Descemet membrane while attempting to separate it from the overlying stroma (more likely with scarring that involves Descemet membrane or a history of a Descemet membrane rupture [spontaneous, as with hydrops, or surgical]). When the rupture is small, the procedure may be completed or, if large, conversion to PK will be needed. If LK is attempted in the presence of a

larger perforation, fluid may accumulate in the space between Descemet membrane and the graft, resulting in a double anterior chamber. Studies comparing the visual results of PK with DALK indicate that DALK patients are less likely to achieve 20/20 vision compared with PK recipients if baring of Descemet membrane is not achieved.¹⁶³ Stromal rejection is another complication of DALK, with an incidence reported between 2% and 12%. While corticosteroid treatment is not needed for endothelial rejections, it may still be necessary to prevent stromal rejection in some cases.¹⁸⁸

Penetrating

Penetrating keratoplasty is particularly useful for treating edema with opacification that involves all layers of the cornea. It may be the procedure of choice if additional anterior segment surgery (i.e., iris reconstruction, cataract removal, IOL exchange, or vitrectomy) is also required.

Indications

The objectives of PK depend on the corneal pathology and related problems. Visual improvement is the most common reason for a full-thickness cornea transplant. When a cornea is thin or perforated, tectonic restoration is often required. A therapeutic transplant for an unresponsive microbial infection is an additional indication. Further, cosmetic transplants are performed in some cases where there is an opacification but where other factors are expected to prevent improvement in vision.

Special Indications and Approaches

Pediatric keratoplasty poses special problems for the cornea surgeon, given the size of the eye, the frequent association with other extra- and intraocular problems, higher incidence of rejection and secondary infection, and limited cooperation by the patient. A careful assessment of the patients' family situation and related support systems is extremely important. Since many of these eyes also have amblyopia, glaucoma, and retinal issues, a team approach involving one or more ophthalmic specialists, the pediatrician and pediatric specialists, and a social worker is extremely helpful.

Crescentic patch grafts and rotational autografts are special forms of PK. Peripheral opacities that are associated with significant tissue loss and increased astigmatism (e.g., Terrien marginal degeneration, postinfectious keratitis) but with a clear central cornea may require either partial or full-thickness grafting. These may take the form of oval or crescentic grafts.^{189,190}

In some situations, a central corneal scar may be managed by an ipsilateral rotational autograft. The graft position is offset (rather than in the more typical central position) so that, on rotation, the scar is shifted into the far periphery.¹⁹¹ Care should be taken to avoid having the graft-host junction too close to the pupil, causing postoperative distortion. Because of the eccentricity of the graft, irregular astigmatism is a common postoperative problem that has limited the application of this approach.¹⁹²

Oversized or tectonic grafts are typically used in conditions of significant peripheral thinning (e.g., decentered keratoconus, pellucid marginal degeneration or keratoglobus) or infection (e.g., sclerokeratitis) when the peripheral edge of the pathologic process extends beyond the central 7.5 to 9.0 mm. In some cases, the treatment should be staged. The first stage is an LK that thickens the stromal bed. The second stage is a conventional PK, done many months later, through the thickened bed. Many of these cases are accompanied by other anterior segment reconstructive procedures (e.g., angle reconstruction, pupilloplasty, lensectomy, or IOL repositioning).

Opacified corneas may at times be associated with serious vitreoretinal pathology (e.g., following accidental or surgical trauma). The opacified cornea will preclude the safe repair of the retina. A temporary plastic or silicone corneal insert—typically referred to as a temporary keratoprosthesis—may be placed at the time of the retinal surgery, left in place for the duration of the retinal procedure, and then removed and replaced with a full-thickness penetrating graft. The view through the temporary keratoprosthesis is excellent and, in most cases, is superior to the view through the alternative, a recently performed corneal transplant.

Femtosecond laser-assisted keratoplasty (FLAK) utilizes the femtosecond laser for trephining both the donor and recipient corneas. Trephine patterns designated as top-hat, mushroom, or zigzag have been studied and have the theoretical advantage of being able to create additional wound surface area that might result in faster wound healing and a stronger wound, when compared with standard trephination techniques. This allows for earlier suture removal and quicker visual rehabilitation.^{174,193-196} With better control of wound healing, management of wound shape and postoperative astigmatism should be improved.^{194,195} In a comparison study of eyes that had undergone femtosecond laser zigzag-shaped PK compared with eyes having conventional PK, there was

a significantly improved rate of visual improvement with 81% versus 45% achieving best spectacle-corrected visual acuity (BSCVA of 20/40 or better within 3 months in the zigzag and conventional group, respectively.¹⁷⁴ Additionally, the zigzag group had average topographic astigmatism of just 3.00 D, compared to 4.46 D in the conventional group.¹⁷⁴

Outcomes

Outcomes, defined as graft clarity and visual improvement, can be quite varied in this diverse group of conditions. In the case of a nonvascularized central scar with no other related ocular damage, the percent achieving graft clarity is well over 90%.¹⁹⁷ This is in contrast to scarring related to a chemical injury where there is also extensive corneal vascularization and limbal stem cell damage, in which the success rate is quite poor. Visual acuity will often depend on whether other factors such as a cataract, glaucomatous damage, or retinal pathology are present. Variable and unpredictable postkeratoplasty astigmatism remains an issue. It is common practice for surgeons to leave sutures in place long term when selective suture removal has achieved a low level of astigmatism and good vision. The disadvantage of this practice is the risk of late suture breakage, irritation, and infection or rejection.^{198,199} Studies have shown that FLAK results in greater improvement in astigmatism in the early postoperative period compared with conventional PK techniques, but astigmatism is equal by 6 months.¹⁹⁴ There is, however, evidence that the overall degree of higher order aberrations and anterior corneal irregularity is improved in FLAK compared with conventional PK.²⁰⁰ Earlier suture removal is possible with FLAK due to greater mechanical stability and wound healing.¹⁹⁵ Access, logistics, and cost of a femtosecond laser may limit its use.

Contraindications

Corneal transplant success is improved by addressing as many active or concomitant problems as possible in advance of the surgery. Good control of IOP, resolution of adnexal and intraocular inflammation and infection (e.g., chronic dacryocystitis, blepharitis, conjunctivitis, keratitis), and repair of any lid abnormality (e.g., trichiasis, entropion, ectropion, lagophthalmos, and exposure) are crucial. The presence of thinned areas in which graft-host thickness mismatch may occur, deep stromal vascularization that may increase the risk of rejection, and ocular surface disease (e.g., dry eye, past chemical or radiation injury, OMMP, or Stevens-Johnson syndrome) are important factors contributive to reduced graft survival.

Complications

Complications can be divided into those that occur during surgery and those that occur afterwards.

Intraoperative

- ◆ Technical complications:
 - ◆ Scleral perforation with fixation suture
 - ◆ Improper trephination
 - ◆ Damaged or lost donor button
 - ◆ Retained Descemet membrane
 - ◆ Iris or lens damage
 - ◆ Torn posterior lens capsule with or without vitreous loss
 - ◆ Anterior chamber or vitreous hemorrhage
 - ◆ Vitreous back pressure
- ◆ Nontechnical complications
 - ◆ Expulsive suprachoroidal hemorrhage

Postoperative

- ◆ Rejection
- ◆ Primary or late graft failure
- ◆ Wound leak or misalignment
- ◆ Persistent epithelial defect
- ◆ Filamentary keratitis
- ◆ Suture-related immune infiltrate
- ◆ Suture infection/abscess
- ◆ Endophthalmitis
- ◆ Elevated IOP
- ◆ Anterior synechia formation
- ◆ Hyphema
- ◆ Choroidal detachment
- ◆ Retinal detachment

- ◆ IOL dislocation
- ◆ Graft dislocation (in EK)

Primary graft failure occurs when the donor tissue fails to clear during the first 4 weeks (EK) or first 8 weeks (PK) postoperatively in the absence of other problems that may be causing stromal edema (e.g., a persistent epithelial defect, elevated IOP, intraoperative events). It is thought to be due to inadequate endothelial cell function because of a damaged endothelium or an inadequate number of cells. It is generally viewed as a problem related to corneal selection, processing, or storage. Fortunately, it is a rare occurrence. Excess trauma or manipulation of the donor tissue at the time of surgery that leads to persistent postoperative stromal edema is not usually defined as primary graft failure. In EK surgery, it may be related to an upside-down graft. Re-grafting is usually necessary.

Endophthalmitis is a rare but disastrous complication of corneal transplantation. In addition to traditional periocular sources, contamination of the donor tissue or storage media are avenues of spread in the immediate and intermediate postoperative periods. Suture loosening or persistent epithelial defects are commonly associated with intermediate or late-onset endophthalmitis.

Late graft failure refers to failure of the donor tissue when it occurs years after the transplant. This is thought to be related to gradual endothelial cell loss,^{89,102,201} but it may be accelerated if prior rejection reactions, infections, traumatic iritis, or elevated IOPs have occurred. Excess manipulation of the donor tissue at the time of surgery, shallowing of the anterior chamber due to wound dehiscence, or repositioning or rubbing of the donor tissue following EK may also contribute to premature graft failure.

Corneal transplant rejection reactions are the most frequent cause of corneal graft failure. Early, aggressive treatment with topical, periocular, and systemic corticosteroids may be able to reverse an endothelial rejection reaction.

Identification of high-risk cases or those with a history of recurrent inflammation (e.g., herpes simplex virus keratitis, zoster, uveitis) is important because standard treatment protocols following PK may need to be augmented with higher daily doses of corticosteroid or oral antiviral agents. Two studies that specifically compared the results of PK and DSAEK in Fuchs dystrophy and PBK showed no statistically significant difference between the two groups with regard to rejection rates.^{70,71} However, more recent studies suggest that the

less allogenic tissue that is implanted into the eye (as in EK tissue), the lower the long-term risk of rejection.⁹³

In 2012, EK surpassed PK as the most commonly performed keratoplasty in the United States.²⁰² Along with the popularity of EK came an increase in case reports of fungal infections, prompting large database studies that confirmed its rise.²⁰³⁻²⁰⁵ Although rare, the incidence of postkeratoplasty fungal infections (most commonly *Candida* species) has grown in recent years from 0.014% in a 2013 report²⁰³ to 0.023% in a 2016 report.²⁰⁴ The additional warming period required for EK processing has been found to be a factor in fungal infections.²⁰⁶ In contrast to the discordance of positive bacterial culture donor rims to clinical infection, multiple studies show positive fungal culture donor rims to have predictive value.^{205,207,208} Aldave et al²⁰³ found that when a donor transmits fungal infection, three quarters of the mate tissues also have a positive rim culture, and two thirds of those transmit infection. This highlights the importance of sharing culture results with the source eye bank so that the mate tissue recipient may be more closely monitored. Currently, there is no consensus as to prophylactic antifungal treatment when a positive fungal culture is discovered. Research on antifungal supplementation of cold corneal-storage media is ongoing.

Keratoprosthesis

Ophthalmologists have pursued the ideal artificial cornea for well over 100 years, with glass as the first material.²⁰⁹ Innovative designs, materials, and surgical procedures have characterized this endeavor. Cardona,²¹⁰ osteo-odonto-keratoprosthesis,²¹¹ AlphaCor,²¹² and the Boston keratoprosthesis²¹³ are designs that have attracted the most interest over the past decades. Significant improvements in the design and postoperative management of the Boston type 1 keratoprosthesis has resulted in a steady rise in the number of these procedures performed both in the United States and abroad.^{214,215} Reduced incidence of postoperative stromal necrosis and bacterial endophthalmitis due to the chronic use of protective soft contact lenses and topical antibiotics has resulted in improved retention and visual outcomes and has had a positive impact on surgeons' perceptions of when to recommend keratoprosthesis.²¹⁴⁻²¹⁷ Once considered a procedure of last resort in patients with severe bilateral visual impairment, it is now being used for a variety of unilateral and bilateral indications, such as ocular trauma,^{218,219} herpetic keratitis,^{220,221} aniridia,²²² and Stevens-Johnson syndrome.²²³

More recently, as corneal surgeons have gained a greater appreciation of the failure rate of repeat corneal transplantation,²²⁴ a role for a keratoprosthesis in cases of multiple graft failure has become clearer.²¹⁵⁻²¹⁷ Despite earlier suggestions,^{225,226} keratoprostheses are not considered ideal for pediatric cases, particularly as primary treatment.

The retention rate of the Boston type 1 keratoprosthesis at 1 year has been reported to be 90% to 92%^{214,227} of patients, with a 2-year retention rate of 80% to 87%.^{214,217,228} Persistent epithelial defects, especially in patients with limbal stem cell deficiency, infectious keratitis, and stromal necrosis play a significant negative role in keratoprosthesis retention.

Visual acuity improved to 20/200 or better in 50% to 89%^{214,216,217,229} and 20/50 or better in 32% to 43%^{214,216} of patients at 1 year. Rapid stabilization of vision in patients with a healthy retina and optic nerve is facilitated by the smooth, spherical front surface of the Boston type 1 keratoprosthesis. Glaucoma is the most challenging postoperative problem following keratoprosthesis surgery.

Unfortunately, the majority of patients currently undergoing keratoprosthesis surgery (as high as 72% to 85%) already have some glaucomatous optic nerve damage prior to receiving the device. (See Table 6 for complications of keratoprosthesis.) The vision loss from glaucoma is potentially preventable, although there is no reliable method to measure IOP after implantation of a keratoprosthesis. When tube-shunt surgery is performed prior to the keratoprosthesis implantation, the rate of worsening of glaucoma in eyes with poorly controlled IOP that requires surgery during a follow-up of an average of 17 months has been reported to be as low as 2%. Others, however, report rates as high as 38%, particularly when patients with other co-morbidities such as autoimmune ocular surface diseases were included. Frequent reassessment of the optic nerve and visual field studies are necessary to monitor these patients optimally and preserve their vision.²³⁰⁻²³² The incidence of postoperative complications tended to decrease significantly over the first 10 years in patients who had Boston keratoprosthesis for previous graft failure.²²⁹

Patients with severe dry eye and autoimmune ocular surface diseases (particularly Stevens-Johnson syndrome and OMMP²³³) remain a difficult management group despite the other successes of the Boston type 1 keratoprosthesis. Primary placement of the Boston keratoprosthesis in this group of patients results in a higher rate of epithelial defects, scleral and corneal necrosis, extrusion, and

endophthalmitis. Some surgeons advocate ocular surface reconstruction with combined keratolimbal allografts or living related allografts prior to placement of the keratoprosthesis. This can potentially lead to improved outcomes in this group.²³⁴ The Boston type 2 keratoprosthesis²¹³ designed to be used through the eyelid and the osteo-odonto-keratoprosthesis have been implanted with some success in this group of patients.²¹¹

TABLE 6 COMPLICATIONS OF KERATOPROSTHESIS*.²³⁵

Complication	Incidence
Glaucoma ²¹⁷	Preexisting in 72.0%–86.0%
Retroprosthetic membrane formation ^{89,214,216,229,236}	25.0%–55.0%
Persistent epithelial defects ²¹⁴	38.0%
Stromal necrosis ²¹⁴	16.0%
Endophthalmitis ²¹⁷	12.5%
Cystoid macular edema ²¹⁴	8.7%
Infectious keratitis ^{214,237}	8.0%
Extrusion of implant	0%–12.5%
Retention failure	25.7% ²²⁹

* NOTE: Changes in prosthetic design, the use of therapeutic hydrophilic contact lenses, and the chronic use of topical antibiotics have reduced the frequency of many of these complications. Complication rates will also vary based on preoperative etiology.

Follow-up Evaluation

Frequent follow-up is necessary in many of these cases to reassess the underlying disease process and make adjustments to the medical or surgical treatment. For the management of corneal edema, the goal of follow-up is to monitor endothelial dysfunction. For the management of corneal opacification, follow-up is required to monitor corneal clarity and the degree of surface irregularity. Coexisting problems, particularly intraocular inflammation and IOP (which may be caused by underlying problems or by treatment), need to be reassessed regularly. (See Appendix 3 for additional information on determination of IOP in diseased or postsurgical corneas.)

PROVIDER AND SETTING

The ophthalmologist in the outpatient setting is best equipped to diagnose many of the conditions that result in corneal opacification and corneal edema. The medical management may also be within the experience and expertise of the comprehensive ophthalmologist. It should be noted that infants and young children may require evaluations under anesthesia to obtain all the information necessary to determine a course of treatment. Superficial keratectomies and excimer laser PTKs can often be performed in the office setting or in minor-procedure suites. However, most other procedures require the facilities and sterile conditions found in an operating room.

COUNSELING AND REFERRAL

Once a definitive diagnosis is made and the related work-up has been completed, a detailed discussion of the causes of the edema or opacity, and of various treatment options, becomes important. When more sophisticated diagnostic or medical management approaches (i.e.,

those exceeding the training or the level of comfort of the treating physician) are required, or if complex surgical treatments may be needed, the corneal subspecialist may be more equipped to handle the situation. At this point, referral for consultation is recommended. Referrals to retina, glaucoma, or pediatric ophthalmic subspecialists may be needed in some situations. Once the condition has been resolved or has stabilized, referral back to the comprehensive ophthalmologist is appropriate. A team approach is often of great advantage, particularly when geography makes subspecialist visits challenging. The primary care physician should be included in the discussion, especially when surgery is being considered. When the disease process or its management is complex, every effort should be made to counsel the patient appropriately. This will enable the patient to understand the challenges involved in care more clearly, to have appropriate expectations, and to make informed decisions.

There is a commercially available point-of-care test to identify Avellino dystrophy in keratorefractive surgery candidates when there is either a family history or clinical findings are inconclusive for this condition. Poor treatment results due to the high incidence of interface deposits have been reported.²³⁸

SOCIOECONOMIC CONSIDERATIONS

Globally, corneal opacity is the fifth leading cause of bilateral blindness.²³⁹ Of the 7 to 9 million people with bilateral corneal blindness, 90% live in the developing world.²⁴⁰ Major investments in public health infrastructure and primary eye care services have built a strong foundation for preventing future corneal blindness, as nearly 80% of all corneal blindness is avoidable.²⁴¹

Corneal diseases are associated with poverty and lead to a marked reduction in life expectancy, especially among children with corneal blindness. Efforts aimed at reducing corneal blindness in the developing world are being managed through primary health interventions to combat trachoma, onchocerciasis, vitamin A deficiency, and ophthalmia neonatorum.²⁴²

The cost of harvesting and preparing donor corneal tissue, with infrastructure setup of eye banks in developing countries, as well as the additional cost of specialized donor preparations such as precutting of tissue with microkeratome or femtosecond lasers adds a financial burden to corneal transplantation. This is weighed against the financial impact of correctable causes of blindness to society.

The socioeconomic impact of corneal blindness relative to cataract blindness is not reflected just by its prevalence but is magnified by the younger age of those with corneal blindness,

with a very high number of disability-adjusted life years. Corneal blindness impacts many in their most productive, child-rearing years compared with the more geriatric population blinded by cataracts.²⁴²

APPENDIX 1. QUALITY OF OPHTHALMIC CARE CORE CRITERIA

*Providing quality care
is the physician's foremost ethical obligation, and is
the basis of public trust in physicians.*

AMA Board of Trustees, 1986

Quality ophthalmic care is provided in a manner and with the skill that is consistent with the best interests of the patient. The discussion that follows characterizes the core elements of such care.

The ophthalmologist is first and foremost a physician. As such, the ophthalmologist demonstrates compassion and concern for the individual, and utilizes the science and art of medicine to help alleviate patient fear and suffering. The ophthalmologist strives to develop and maintain clinical skills at the highest feasible level, consistent with the needs of patients, through training and continuing education. The ophthalmologist evaluates those skills and medical knowledge in relation to the needs of the patient and responds accordingly. The ophthalmologist also ensures that needy patients receive necessary care directly or through referral to appropriate persons and facilities that will provide such care, and he or she supports activities that promote health and prevent disease and disability.

The ophthalmologist recognizes that disease places patients in a disadvantaged, dependent state. The ophthalmologist respects the dignity and integrity of his or her patients, and does not exploit their vulnerability.

Quality ophthalmic care has the following optimal attributes, among others.

- ◆ The essence of quality care is a meaningful partnership relationship between patient and physician. The ophthalmologist strives to communicate effectively with his or her patients, listening carefully to their needs and concerns. In turn, the ophthalmologist educates his or her patients about the nature and prognosis of their condition and about proper and appropriate therapeutic modalities. This is to ensure their meaningful participation (appropriate to their unique physical, intellectual, and emotional state) in decisions affecting their management and care, to improve their motivation and compliance with the agreed plan of treatment, and to help alleviate their fears and concerns.
- ◆ The ophthalmologist uses his or her best judgment in choosing and timing appropriate diagnostic and therapeutic modalities as well as the frequency of evaluation and follow-up, with due regard to the urgency and nature of the patient's condition and unique needs and desires.
- ◆ The ophthalmologist carries out only those procedures for which he or she is adequately trained, experienced, and competent, or, when necessary, is assisted by someone who is, depending on the urgency of the problem and availability and accessibility of alternative providers.
- ◆ Patients are assured access to, and continuity of, needed and appropriate ophthalmic care, which can be described as follows.
 - ◆ The ophthalmologist treats patients with due regard to timeliness, appropriateness, and his or her own ability to provide such care.
 - ◆ The operating ophthalmologist makes adequate provision for appropriate pre- and postoperative patient care.
 - ◆ When the ophthalmologist is unavailable for his or her patient, he or she provides appropriate alternate ophthalmic care, with adequate mechanisms for informing patients of the existence of such care and procedures for obtaining it.
 - ◆ The ophthalmologist refers patients to other ophthalmologists and eye care providers based on the timeliness and appropriateness of such referral, the patient's needs, the competence and qualifications of the person to whom the referral is made, and access and availability.
 - ◆ The ophthalmologist seeks appropriate consultation with due regard to the nature of the ocular or other medical or surgical problem. Consultants are suggested for their skill, competence, and accessibility. They receive as complete and accurate an accounting of the problem as necessary to provide efficient and effective advice or intervention, and in turn they respond in an adequate and timely manner.

- ◆ The ophthalmologist maintains complete and accurate medical records.
- ◆ On appropriate request, the ophthalmologist provides a full and accurate rendering of the patient's records in his or her possession.
- ◆ The ophthalmologist reviews the results of consultations and laboratory tests in a timely and effective manner and takes appropriate actions.
- ◆ The ophthalmologist and those who assist in providing care identify themselves and their profession.
- ◆ For patients whose conditions fail to respond to treatment and for whom further treatment is unavailable, the ophthalmologist provides proper professional support, counseling, rehabilitative and social services, and referral as appropriate and accessible.
- ◆ Prior to therapeutic or invasive diagnostic procedures, the ophthalmologist becomes appropriately conversant with the patient's condition by collecting pertinent historical information and performing relevant preoperative examinations. Additionally, he or she enables the patient to reach a fully informed decision by providing an accurate and truthful explanation of the diagnosis; the nature, purpose, risks, benefits, and probability of success of the proposed treatment and of alternative treatment; and the risks and benefits of no treatment.
- ◆ The ophthalmologist adopts new technology (e.g., drugs, devices, surgical techniques) in judicious fashion, appropriate to the cost and potential benefit relative to existing alternatives and to its demonstrated safety and efficacy.
- ◆ The ophthalmologist enhances the quality of care he or she provides by periodically reviewing and assessing his or her personal performance in relation to established standards, and by revising or altering his or her practices and techniques appropriately.
- ◆ The ophthalmologist improves ophthalmic care by communicating to colleagues, through appropriate professional channels, knowledge gained through clinical research and practice. This includes alerting colleagues of instances of unusual or unexpected rates of complications and problems related to new drugs, devices, or procedures.
- ◆ The ophthalmologist provides care in suitably staffed and equipped facilities adequate to deal with potential ocular and systemic complications requiring immediate attention.
- ◆ The ophthalmologist also provides ophthalmic care in a manner that is cost effective without unacceptably compromising accepted standards of quality.

Reviewed by: Council
Approved by: Board of Trustees
October 12, 1988

2nd Printing: January 1991
3rd Printing: August 2001
4th Printing: July 2005

APPENDIX 2. INTERNATIONAL STATISTICAL CLASSIFICATION OF DISEASES AND RELATED HEALTH PROBLEMS (ICD) CODES

Corneal edema, which includes entities with the following ICD-10 classifications:

	ICD-10 CM
Idiopathic corneal edema	H18.22-
Secondary corneal edema	H18.23-
Bullous keratopathy	H18.11-
	H18.21-
Corneal edema due to wearing contact lenses	(corneal edema secondary to contact lenses)
Congenital glaucoma	Q15.0
Congenital hereditary endothelial dystrophy – autosomal dominant (CHED – AD)	H18.51
Congenital hereditary endothelial dystrophy – autosomal recessive (CHED – AR)	H18.51
Posterior polymorphous corneal dystrophy (PPCD)	H18.59
Intraocular inflammation	H57.8
Birth/forceps delivery trauma	P15.3
Acute angle-closure glaucoma	H40.21-
Fuchs dystrophy	H18.51
Primary hypotony	H44.44-
Hypoxia	R09.02
Iridocorneal endothelial (ICE) syndrome	H18.89-
Infectious keratitis	H16.8
Keratoconus – hydrops	H18.62-
Pseudophakic or aphakic bullous keratopathy (unilateral or bilateral)	H18.1-
Direct injury (surgical trauma)	T81.31XA

CM = Clinical Modification used in the United States; ICD = International Classification of Diseases

Corneal opacification, which includes entities with the following ICD-10 classifications:

	ICD-10 CM
Minor corneal opacity	H17.81-
Peripheral corneal opacity	H17.82-
Central corneal opacity	H17.1-
Phthisical cornea	A18.59, H44.52-

CM = Clinical Modification used in the United States; ICD = International Classification of Diseases

Additional Information for ICD-10 Codes:

- Certain ICD-10 CM categories have applicable 7th characters. The applicable 7th character is required for all codes within the category, or as the notes in the Tabular List instruct. The 7th character must always be the 7th character in the data field. If a code that requires a 7th character is not 6 characters, a placeholder X must be used to fill in the empty characters.
- For bilateral sites, the final character of the codes in the ICD-10 CM indicates laterality. If no bilateral code is provided and the condition is bilateral, assign separate codes for both the left and right side. Unspecified codes should only be used when there is no other code option available.
- When the diagnosis code specifies laterality, regardless of which digit it is found in (i.e., 4th digit, 5th digit, or 6th digit):
 - Right is always 1
 - Left is always 2
 - Bilateral is always 3

APPENDIX 3: DETERMINATION OF INTRAOCULAR PRESSURE IN DISEASED OR POSTSURGICAL CORNEAS

Intraocular pressure (IOP) assessment in diseased corneas may be very inaccurate when measured only by Goldmann applanation tonometry (GAT). This is due to a host of reasons, such as disease-induced and treatment-induced alterations in corneal thickness, hydration state, corneal curvature/astigmatism, an irregular corneal epithelial surface, or corneal stromal scarring. All of these factors can affect the estimation of the inherently subjective endpoint of GAT (i.e., the “just touching” inside edges of the semicircular mires viewed through the Goldmann applanation prism tip). Therefore, use of alternative and less subjective techniques for IOP determination in these diseased, abnormal, or surgically altered corneas is strongly advised. Such techniques are described below.

- ◆ Applanation techniques, which are measured using the following technology:
 - ◆ Pneumotonometer. This technology uses a pneumatic sensor (consisting of a piston floating on an air bearing) with a 5-mm fenestrated silicone tip that conforms to the cornea. The balance between the flow of air from the machine and the resistance to flow from the cornea affects the movement of the piston, and this movement is used to calculate the IOP. This device generates 40 readings per second and also measures ocular pulse amplitude. Topical anesthesia is required.
 - ◆ Non-Goldmann applanation tonometer. This technology utilizes a free-floating 1-mm micro-strain gauge transducer to detect transmitted IOP. The transducer is surrounded by an outer ring that flattens the adjacent cornea, reducing its influence on measurement. These devices measure 500 samples per second and average 8 or 10 readings for each IOP determination within confidence limits. Topical anesthesia is required.
 - ◆ Ocular response analyzer. This technology uses a collimated air pulse to cause the cornea to move inward and then outward, in a bi-directional applanation process, to measure the biomechanical properties of the cornea (i.e., hysteresis) and calculate a “corneal-compensated” and GAT-equivalent IOP. This technology also measures ocular pulse amplitude and does not require topical anesthesia.
- ◆ The contour-matching Pascal technique (dynamic contour tonometer) utilizes a piezoresistive sensor embedded into the tonometer tip to digitally sample IOP 100 times per second. The concave tip shape causes a relaxation of the cornea to conform to the dynamic contour tonometer tip and minimizes any influence of corneal properties on IOP measurements. An internal microprocessor then analyzes this direct proportional signal and extracts IOP and ocular pulse amplitude. In this way, the device calculates an IOP independent of corneal properties. It requires 6 seconds or 6 ocular pulse cycles to determine the IOP, and it requires topical anesthesia. This is mounted to the slit lamp.

- ◆ The rebound tonometry deceleration technique utilizes an induction coil to magnetize a small plastic-tipped metal probe, which is rapidly fired against the cornea (0.25 m/sec). Software analyzes the rate of deceleration, the contact time of the probe against the cornea (approximately 0.05 sec), and the relative magnitude of which is proportional to IOP, from which the IOP is calculated. Six measurements are required for accuracy. This technology does not require topical anesthesia.
- ◆ The Mackay-Marg tonometer combines mechanisms of both applanation and indentation. This is available as a small, handheld, battery-powered device that requires topical anesthesia. The tonometer has a small applanating plunger from which the IOP is read electronically. Multiple readings are averaged.

Although applanation and rebound tonometers are more influenced by corneal properties than other devices, they are more objective than GAT. Therefore, they may more accurately and reproducibly estimate “true IOP” (relative to GAT) over the course of a patient’s corneal disease state. Nevertheless, it is very important to use the same valid technique consistently, from visit to visit, to detect clinically significant and meaningful IOP elevations. Early detection of elevated IOP will allow timely initiation of IOP-lowering therapy before irreversible optic nerve damage occurs. These eyes are frequently subject to either disease- or treatment-induced secondary IOP elevation, which often goes undetected when relying on GAT alone to determine IOP.

LITERATURE SEARCHES FOR THIS PPP

Literature searches of the PubMed and Cochrane databases were conducted in March 2017; the search strategies were as follows. Specific limited update searches were conducted after June 2018.

Treatment:

Edema/surgery/keratoplasty/DSEK/EK/PTK: (corneal edema/surgery[mh]) AND (Keratoplasty, Penetrating[mh] OR Descemet Stripping Endothelial Keratoplasty[mh] OR endothelial keratoplasty[tiab] OR phototherapeutic keratectomy[tiab] OR Gunderson[tiab] OR (amniotic[tiab] OR anterior stromal punct*[tiab]))

Edema/surgery/transplantation

(corneal edema/surgery[mh]) AND (Corneal Transplantation/methods[mh])

Edema/therapy:

(corneal edema/drug therapy[mh] OR corneal edema/therapy[mh]) AND (sodium chloride[tiab] OR Saline Solution, Hypertonic[mh] OR hair dryer[tiab] OR bandage soft contact lens*[tiab] OR Contact Lenses[mh] OR Intraocular Pressure[mh] OR Steroids[mh] OR Antiviral Agents[mh] OR Anti-Bacterial Agents[mh])

Opacity/surgery/keratoplasty:

(corneal opacity/surgery[mh]) AND (lamellar keratoplasty[tiab] OR superficial keratectomy[tiab] OR phototherapeutic keratectomy[tiab] OR microkeratome*[tiab] OR femtosecond[tiab] OR free-hand[tiab] OR Keratoplasty, Penetrating[mh] OR keratoprosthesis*[tiab] OR EDTA[tiab] OR Ethylenediaminetetraacetic acid[tiab])

Opacity/surgery/transplantation:

(corneal opacity/surgery[mh]) AND (Corneal Transplantation/methods[mh])

Opacity/therapy:

(corneal opacity/drug therapy[mh] OR corneal opacity/therapy[mh]) AND (Contact Lenses[mh] OR bandage soft contact lens*[tiab] OR Anti-Inflammatory Agents[mh] OR Anti-Infective Agents[mh])

Corneal diseases/surgery/transplantation:

Corneal Diseases/surgery[MAJR] AND Corneal Transplantation[MAJR]

Edema/keratoplasty/DSEK/DLEK/PTK:

(corneal edema*[tiab] OR corneal oedema*[tiab]) AND (keratoplasty[tiab] OR DSEK[tiab] OR

DMEK[tiab] OR DLEK [tiab] OR PK[tiab] OR PTK[tiab] OR phototherapeutic keratectomy[tiab] OR anterior stromal[tiab] OR Gunderson[tiab] OR amniotic[tiab])

Opacity/keratoplasty/ALTK/HALK/DALK:

(cornea*[tiab] AND opaci*[tiab]) AND (keratectom*[tiab]) OR (keratoplast*[tiab] OR ALTK[tiab] OR HALK[tiab] OR DALK[tiab] OR keratoplasty[tiab] OR PK[tiab] OR keratoprosthesis*[tiab] OR EDTA[tiab] OR Ethylenediaminetetraacetic acid[tiab])

Diagnosis:

(Edema/diagnosis: (corneal edema/diagnosis[MAJR]) AND (pachymetr*[tiab]) OR corneal edema/ultrasonography[mh] OR ultrasound[tiab] OR ultrasonograph*[tiab] OR specular[tiab]) OR (corneal edema/diagnosis[MAJR]) AND (Diagnostic Techniques, Ophthalmological[mh])

Opacity/diagnosis:

(corneal opacity/diagnosis[MAJR]) AND (Tomography, Optical Coherence[mh] OR Microscopy, Confocal[mh] OR potential acuity[tiab] OR overrefract*[tiab] OR corneal opacity/ultrasonography[mh] OR ultrasound[tiab] OR ultrasonograph*[tiab]) OR (corneal opacity/diagnosis[MAJR]) AND Diagnostic Techniques, Ophthalmological[mh])

Pathology/Physiology/Physiopathology:

Edema/pathology/physiology/physiopathology: ("corneal edema/pathology"[MAJR] OR "corneal edema/physiology"[MAJR] OR "corneal edema/physiopathology"[MAJR])

Opacity/pathology/physiology/physiopathology:

("corneal opacity/pathology"[MAJR] OR "corneal opacity/physiology"[MAJR] OR "corneal opacity/physiopathology"[MAJR])

Socioeconomic:

("corneal edema"[All Fields] OR "corneal opacity"[All Fields]) AND (economics[All Fields] OR economics[MeSH Terms] OR cost[All Fields] OR cost[MeSH Terms] OR "quality of life"[All Fields] OR QoL[All Fields] OR quality of life[MeSH Terms] OR burden[All Fields] OR burden of illness[MESH Terms])

RELATED ACADEMY MATERIALS

Basic and Clinical Science Course

External Disease and Cornea (Section 8, 2018–2019)

Focal Points

IOL Power Calculation in Patients with Prior Corneal Refractive Surgery (2013)

Cystoid Macular Edema Module (2014)

Patient Education Brochure

Corneal Abrasion and Erosion (2014)

Preferred Practice Pattern® Guidelines – Free download available at www.aao.org/ppp.

Comprehensive Adult Medical Eye Evaluation (2015)

Pediatric Eye Evaluations (2017)

REFERENCES

1. Scottish Intercollegiate Guidelines Network (SIGN). *SIGN 50: a guideline developer's handbook*. Edinburgh: SIGN; 2015. (SIGN publication no. 50). [November 2015]. Available from URL: <http://www.sign.ac.uk>.
2. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336(7650):924-926.
3. GRADE Working Group. Organizations that have endorsed or that are using GRADE. <http://www.gradeworkinggroup.org/>. Accessed September 19, 2018.
4. Schmid KE, Kornek GV, Scheithauer W, Binder S. Update on ocular complications of systemic cancer chemotherapy. *Surv Ophthalmol*. 2006;51(1):19-40.
5. Feder RS, Olsen TW, Prum BE, Jr., et al. Comprehensive Adult Medical Eye Evaluation Preferred Practice Pattern((R)) Guidelines. *Ophthalmology*. 2016;123(1):P209-236. www.aaojournal.org/content/preferred-practice-pattern or www.aao.org/ppp. Accessed May 230, 2017.
6. Nevyas AS, Raber IM, Eagle RC, Jr., Wallace IB, Nevyas HJ. Acute band keratopathy following intracameral Viscoat. *Arch Ophthalmol*. 1987;105(7):958-964.
7. Freddo TF, Leibowitz HM. Bilateral acute corneal calcification. *Ophthalmology*. 1985;92(4):537-542.
8. Honig MA, Barraquer J, Perry HD, Riquelme JL, Green WR. Forceps and vacuum injuries to the cornea: histopathologic features of twelve cases and review of the literature. *Cornea*. 1996;15(5):463-472.
9. Gahl WA, Kuehl EM, Iwata F, Lindblad A, Kaiser-Kupfer MI. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. *Mol Genet Metab*. 2000;71(1-2):100-120.
10. Summers CG, Purple RL, Krivit W, et al. Ocular changes in the mucopolysaccharidoses after bone marrow transplantation. A preliminary report. *Ophthalmology*. 1989;96(7):977-984; discussion 984-975.
11. van der Meulen IJ, Patel SV, Lapid-Gortzak R, Nieuwendaal CP, McLaren JW, van den Berg TJ. Quality of vision in patients with Fuchs endothelial dystrophy and after Descemet stripping endothelial keratoplasty. *Arch Ophthalmol*. 2011;129(12):1537-1542.
12. Wacker K, McLaren JW, Amin SR, Baratz KH, Patel SV. Corneal high-order aberrations and backscatter in Fuchs' endothelial corneal dystrophy. *Ophthalmology*. 2015;122(8):1645-1652.
13. Jeng BH, Galor A, Lee MS, et al. Amantadine-associated corneal edema potentially irreversible even after cessation of the medication. *Ophthalmology*. 2008;115(9):1540-1544.
14. Naumann GO, Schlotzer-Schrehardt U. Amantadine-associated corneal edema. *Ophthalmology*. 2009;116(6):1230-1231; author reply 1231.
15. Park CY, Chuck RS. Sudden bilateral corneal oedema in a patient with Parkinson's disease. *Acta Ophthalmol*. 2011;89(2):198-199.
16. Varley GA, Meisler DM, Benes SC, McMahan JT, Zakov ZN, Fryczkowski A. Hibiclens keratopathy: a clinicopathologic case report. *Cornea*. 1990;9(4):341-346.
17. Raizman MB, Hamrah P, Holland EJ, et al. Drug-induced corneal epithelial changes. *Surv Ophthalmol*. 2017;62(3):286-301.
18. Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. *Drug Saf*. 2008;31(2):127-141.
19. Kaplan LJ, Cappaert WE. Amiodarone keratopathy. Correlation to dosage and duration. *Arch Ophthalmol*. 1982;100(4):601-602.
20. Jhanji V, Rapuano CJ, Vajpayee RB. Corneal calcific band keratopathy. *Curr Opin Ophthalmol*. 2011;22(4):283-289.
21. Jeganathan VS, Wirth A, MacManus MP. Ocular risks from orbital and periorbital radiation therapy: a critical review. *Int J Radiat Oncol Biol Phys*. 2011;79(3):650-659.
22. Smith GT, Deutsch GP, Cree IA, Liu CS. Permanent corneal limbal stem cell dysfunction following radiotherapy for orbital lymphoma. *Eye (Lond)*. 2000;14(Pt 6):905-907.
23. Papathanassiou M, Nikita E, Theodossiadis P, Theodossiadis GP, Vergados I. Exemestane-induced corneal epithelial changes. *Cutan Ocul Toxicol*. 2010;29(3):209-211.
24. Yeh S, Fine HA, Smith JA. Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma. *Cornea*. 2009;28(6):699-702.
25. Van Meter WS. Central corneal opacification resulting from recent chemotherapy in corneal donors. *Trans Am Ophthalmol Soc*. 2007;105:207-212; discussion 212-203.

26. Serle JB, Katz LJ, McLaurin E, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). *Am J Ophthalmol.* 2018;186:116-127.
27. Miglior S, Albe E, Guareschi M, Mandelli G, Gomasasca S, Orzalesi N. Intraobserver and interobserver reproducibility in the evaluation of ultrasonic pachymetry measurements of central corneal thickness. *Br J Ophthalmol.* 2004;88(2):174-177.
28. Garcia-Medina JJ, Garcia-Medina M, Garcia-Maturana C, Zanon-Moreno V, Pons-Vazquez S, Pinazo-Duran MD. Comparative study of central corneal thickness using fourier-domain optical coherence tomography versus ultrasound pachymetry in primary open-angle glaucoma. *Cornea.* 2013;32(1):9-13.
29. Fante RJ, Shtein RM, Titus MS, Woodward MA. Anterior segment optical coherence tomography versus ultrasound pachymetry to measure corneal thickness in endothelial keratoplasty donor corneas. *Cornea.* 2013;32:e79-82.
30. Wirbelauer C, Scholz C, Hoerauf H, Pham DT, Laqua H, Birngruber R. Noncontact corneal pachymetry with slit lamp-adapted optical coherence tomography. *Am J Ophthalmol.* 2002;133(4):444-450.
31. Zhao PS, Wong TY, Wong WL, Saw SM, Aung T. Comparison of central corneal thickness measurements by visante anterior segment optical coherence tomography with ultrasound pachymetry. *Am J Ophthalmol.* 2007;143(6):1047-1049.
32. Kim HY, Budenz DL, Lee PS, Feuer WJ, Barton K. Comparison of central corneal thickness using anterior segment optical coherence tomography vs ultrasound pachymetry. *Am J Ophthalmol.* 2008;145(2):228-232.
33. Brandt JD, Beiser JA, Kass MA, Gordon MO. Ocular Hypertension Treatment Study (OHTS) Group. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). *Ophthalmology.* 2001;108(10):1779-1788.
34. Iyamu E, Osuobeni E. Age, gender, corneal diameter, corneal curvature and central corneal thickness in Nigerians with normal intra ocular pressure. *J Optom.* 2012;5:87-97.
35. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern® Guidelines. Corneal Ectasia. San Francisco, CA: American Academy of Ophthalmology; 2018. www.aao.org/ppp.
36. Hirst LW, Yamauchi K, Enger C, Vogelpohl W, Whittington V. Quantitative analysis of wide-field specular microscopy. II. Precision of sampling from the central corneal endothelium. *Invest Ophthalmol Vis Sci.* 1989;30(9):1972-1979.
37. Mustonen RK, McDonald MB, Srivannaboon S, Tan AL, Doubrava MW, Kim CK. In vivo confocal microscopy of Fuchs' endothelial dystrophy. *Cornea.* 1998;17(5):493-503.
38. Edelhauser HF. The balance between corneal transparency and edema: the Proctor Lecture. *Invest Ophthalmol Vis Sci.* 2006;47(5):1754-1767.
39. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. *Surv Ophthalmol.* 2008;53 Suppl 1:S93-105.
40. Aydin S, Ozcura F. Corneal oedema and acute anterior uveitis after two doses of travoprost. *Acta Ophthalmol Scand.* 2007;85(6):693-694.
41. Wirtitsch MG, Findl O, Heinzl H, Drexler W. Effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttata. *Arch Ophthalmol.* 2007;125(10):1345-1350.
42. Egan CA, Hodge DO, McLaren JW, Bourne WM. Effect of dorzolamide on corneal endothelial function in normal human eyes. *Invest Ophthalmol Vis Sci.* 1998;39(1):23-29.
43. Foulks GN, Harvey T, Raj CV. Therapeutic contact lenses: the role of high-Dk lenses. *Ophthalmol Clin North Am.* 2003;16(3):455-461.
44. Luchs JI, Cohen EJ, Rapuano CJ, Laibson PR. Ulcerative keratitis in bullous keratopathy. *Ophthalmology.* 1997;104(5):816-822.
45. DeVoe AG. Electrocautery of Bowman's membrane. *Arch Ophthalmol.* 1966;76(6):768-771.
46. Cormier G, Brunette I, Boisjoly HM, LeFrancois M, Shi ZH, Guertin MC. Anterior stromal punctures for bullous keratopathy. *Arch Ophthalmol.* 1996;114(6):654-658.
47. Wood TO, McLaughlin BJ, Boykins LG. Electron microscopy of corneal surface microdiathermy. *Curr Eye Res.* 1985;4(8):885-895.
48. Maini R, Sullivan L, Snibson GR, Taylor HR, Loughnan MS. A comparison of different depth ablations in the treatment of painful bullous keratopathy with phototherapeutic keratectomy. *Br J Ophthalmol.* 2001;85(8):912-915.
49. Rosa N, Cennamo G. Phototherapeutic keratectomy for relief of pain in patients with pseudophakic corneal edema. *J Refract Surg.* 2002;18(3):276-279.
50. Lin PY, Wu CC, Lee SM. Combined phototherapeutic keratectomy and therapeutic contact lens for recurrent erosions in bullous keratopathy. *Br J Ophthalmol.* 2001;85(8):908-911.

51. Chawla B, Sharma N, Tandon R, Kalaivani M, Titiyal JS, Vajpayee RB. Comparative evaluation of phototherapeutic keratectomy and amniotic membrane transplantation for management of symptomatic chronic bullous keratopathy. *Cornea*. 2010;29(9):976-979.
52. Mannan R, Pruthi A, Rampal U. Combined phototherapeutic keratectomy and amniotic membrane grafts for symptomatic bullous keratopathy. *Cornea*. 2010;29(10):1207-1208; author reply 1208-1209.
53. Thomann U, Meier-Gibbons F, Schipper I. Phototherapeutic keratectomy for bullous keratopathy. *Br J Ophthalmol*. 1995;79(4):335-338.
54. Koenig SB. Annular keratotomy for the treatment of painful bullous keratopathy. *Am J Ophthalmol*. 1996;121(1):93-94.
55. Gundersen T. Conjunctival flaps in the treatment of corneal disease with reference to a new technique of application. *AMA Arch Ophthalmol*. 1958;60(5):880-888.
56. Guell JL, Morral M, Gris O, Elies D, Manero F. Treatment of symptomatic bullous keratopathy with poor visual prognosis using a modified Gundersen conjunctival flap and amniotic membrane. *Ophthalmic Surg Lasers Imaging*. 2012;43(6):508-512.
57. Sonmez B, Kim BT, Aldave AJ. Amniotic membrane transplantation with anterior stromal micropuncture for treatment of painful bullous keratopathy in eyes with poor visual potential. *Cornea*. 2007;26(2):227-229.
58. Espana EM, Grueterich M, Sandoval H, et al. Amniotic membrane transplantation for bullous keratopathy in eyes with poor visual potential. *J Cataract Refract Surg*. 2003;29(2):279-284.
59. Pires RT, Tseng SC, Prabhasawat P, et al. Amniotic membrane transplantation for symptomatic bullous keratopathy. *Arch Ophthalmol*. 1999;117(10):1291-1297.
60. Mejia LF, Santamaria JP, Acosta C. Symptomatic management of postoperative bullous keratopathy with nonpreserved human amniotic membrane. *Cornea*. 2002;21(4):342-345.
61. Georgiadis NS, Ziakas NG, Boboridis KG, Terzidou C, Mikropoulos DG. Cryopreserved amniotic membrane transplantation for the management of symptomatic bullous keratopathy. *Clin Experiment Ophthalmol*. 2008;36(2):130-135.
62. Pavlovic I, Shajari M, Herrmann E, Schmack I, Lencova A, Kohnen T. Meta-analysis of postoperative outcome parameters comparing descemet membrane endothelial keratoplasty versus descemet stripping automated endothelial keratoplasty. *Cornea*. 2017;36(12):1445-1451.
63. Deng SX, Lee WB, Hammersmith KM, et al. Descemet membrane endothelial keratoplasty: safety and outcomes: a report by the american academy of ophthalmology. *Ophthalmology*. 2018;125(2):295-310.
64. Streilein JW. New thoughts on the immunology of corneal transplantation. *Eye (Lond)*. 2003;17(8):943-948.
65. Jonas JB, Rank RM, Budde WM. Immunologic graft reactions after allogenic penetrating keratoplasty. *Am J Ophthalmol*. 2002;133(4):437-443.
66. Claesson M, Armitage WJ, Fagerholm P, Stenevi U. Visual outcome in corneal grafts: a preliminary analysis of the Swedish Corneal Transplant Register. *Br J Ophthalmol*. 2002;86(2):174-180.
67. Allan BD, Terry MA, Price FW, Jr., Price MO, Griffin NB, Claesson M. Corneal transplant rejection rate and severity after endothelial keratoplasty. *Cornea*. 2007;26(9):1039-1042.
68. Wu EI, Ritterband DC, Yu G, Shields RA, Seedor JA. Graft rejection following descemet stripping automated endothelial keratoplasty: features, risk factors, and outcomes. *Am J Ophthalmol*. 2012;153(5):949-957.
69. Jordan CS, Price MO, Trespalacios R, Price FW, Jr. Graft rejection episodes after Descemet stripping with endothelial keratoplasty: part one: clinical signs and symptoms. *Br J Ophthalmol*. 2009;93(3):387-390.
70. Price MO, Gorovoy M, Benetz BA, et al. Descemet's stripping automated endothelial keratoplasty outcomes compared with penetrating keratoplasty from the Cornea Donor Study. *Ophthalmology*. 2010;117(3):438-444.
71. Price MO, Jordan CS, Moore G, Price FW, Jr. Graft rejection episodes after Descemet stripping with endothelial keratoplasty: part two: the statistical analysis of probability and risk factors. *Br J Ophthalmol*. 2009;93(3):391-395.
72. Price MO, Scanameo A, Feng MT, Price FW, Jr. Descemet's membrane endothelial keratoplasty: risk of immunologic rejection episodes after discontinuing topical corticosteroids. *Ophthalmology*. 2016;123(6):1232-1236.
73. Sugar A, Tanner JP, Dontchev M, et al. Corneal Donor Study Investigator Group. Recipient risk factors for graft failure in the cornea donor study. *Ophthalmology*. 2009;116(6):1023-1028.
74. Price MO, Fairchild KM, Price DA, Price FW, Jr. Descemet's stripping endothelial keratoplasty five-year graft survival and endothelial cell loss. *Ophthalmology*. 2011;118(4):725-729.
75. Thompson RW, Jr., Price MO, Bowers PJ, Price FW, Jr. Long-term graft survival after penetrating keratoplasty. *Ophthalmology*. 2003;110(7):1396-1402.

76. Elder MJ, Stack RR. Globe rupture following penetrating keratoplasty: how often, why, and what can we do to prevent it? *Cornea*. 2004;23(8):776-780.
77. Perl T, Charlton KH, Binder PS. Disparate diameter grafting. Astigmatism, intraocular pressure, and visual acuity. *Ophthalmology*. 1981;88(8):774-781.
78. Samples JR, Binder PS. Visual acuity, refractive error, and astigmatism following corneal transplantation for pseudophakic bullous keratopathy. *Ophthalmology*. 1985;92(11):1554-1560.
79. Troutman RC, Gaster RN. Surgical advances and results of keratoconus. *Am J Ophthalmol*. 1980;90(2):131-136.
80. Perlman EM. An analysis and interpretation of refractive errors after penetrating keratoplasty. *Ophthalmology*. 1981;88(1):39-45.
81. Lee WB, Jacobs DS, Musch DC, Kaufman SC, Reinhart WJ, Shtein RM. Descemet's stripping endothelial keratoplasty: safety and outcomes: a report by the American Academy of Ophthalmology. *Ophthalmology*. 2009;116(9):1818-1830.
82. Price MO, Baig KM, Brubaker JW, Price FW, Jr. Randomized, prospective comparison of precut vs surgeon-dissected grafts for descemet stripping automated endothelial keratoplasty. *Am J Ophthalmol*. 2008;146(1):36-41.
83. Covert DJ, Koenig SB. New triple procedure: Descemet's stripping and automated endothelial keratoplasty combined with phacoemulsification and intraocular lens implantation. *Ophthalmology*. 2007;114(7):1272-1277.
84. Dickman MM, Kruit PJ, Remeijer L, et al. A randomized multicenter clinical trial of ultrathin descemet stripping automated endothelial keratoplasty (DSAEK) versus DSAEK. *Ophthalmology*. 2016;123(11):2276-2284.
85. von Marchtaler PV, Weller JM, Kruse FE, Tourtas T. Air versus sulfur hexafluoride gas tamponade in descemet membrane endothelial keratoplasty: a fellow eye comparison. *Cornea*. 2018;37(1):15-19.
86. Oellerich S, Baydoun L, Peraza-Nieves J, et al. Multicenter study of 6-month clinical outcomes after descemet membrane endothelial keratoplasty. *Cornea*. 2017;36(12):1467-1476.
87. Nagra PK, Hammersmith KM, Rapuano CJ, Laibson PR, Cohen EJ. Wound dehiscence after penetrating keratoplasty. *Cornea*. 2006;25(2):132-135.
88. Renucci AM, Marangon FB, Culbertson WW. Wound dehiscence after penetrating keratoplasty: clinical characteristics of 51 cases treated at Bascom Palmer Eye Institute. *Cornea*. 2006;25(5):524-529.
89. Ing JJ, Ing HH, Nelson LR, Hodge DO, Bourne WM. Ten-year postoperative results of penetrating keratoplasty. *Ophthalmology*. 1998;105(10):1855-1865.
90. Hamzaoglu EC, Straiko MD, Mayko ZM, Sales CS, Terry MA. The first 100 eyes of standardized Descemet stripping automated endothelial keratoplasty versus standardized Descemet membrane endothelial keratoplasty. *Ophthalmology*. 2015;122(11):2193-2199.
91. Price MO, Giebel AW, Fairchild KM, Price FW, Jr. Descemet's membrane endothelial keratoplasty: prospective multicenter study of visual and refractive outcomes and endothelial survival. *Ophthalmology*. 2009;116(12):2361-2368.
92. Dapena I, Ham L, Droustas K, van Dijk K, Moutsouris K, Melles GR. Learning curve in Descemet's membrane endothelial keratoplasty: first series of 135 consecutive cases. *Ophthalmology*. 2011;118(11):2147-2154.
93. Anshu A, Price MO, Price FW, Jr. Risk of corneal transplant rejection significantly reduced with Descemet's membrane endothelial keratoplasty. *Ophthalmology*. 2012;119(3):536-540.
94. Price MO, Lisek M, Feng MT, Price FW, Jr. Effect of donor and recipient diabetes status on Descemet membrane endothelial keratoplasty adherence and survival. *Cornea*. 2017;36(10):1184-1188.
95. Forster RK. A comparison of two selective interrupted suture removal techniques for control of post keratoplasty astigmatism. *Trans Am Ophthalmol Soc*. 1997;95:193-214; discussion 214-120.
96. Dirisamer M, Ham L, Dapena I, et al. Efficacy of Descemet membrane endothelial keratoplasty: clinical outcome of 200 consecutive cases after a learning curve of 25 cases. *Arch Ophthalmol*. 2011;129(11):1435-1443.
97. Guerra FP, Anshu A, Price MO, Giebel AW, Price FW. Descemet's membrane endothelial keratoplasty: prospective study of 1-year visual outcomes, graft survival, and endothelial cell loss. *Ophthalmology*. 2011;118(12):2368-2373.
98. Serdarevic ON, Renard GJ, Pouliquen Y. Randomized clinical trial of penetrating keratoplasty. Before and after suture removal comparison of intraoperative and postoperative suture adjustment. *Ophthalmology*. 1995;102(10):1497-1503.
99. Bartels MC, van Rooij J, Geerards AJ, Mulder PG, Remeijer L. Comparison of complication rates and postoperative astigmatism between nylon and mersilene sutures for corneal transplants in patients with Fuchs endothelial dystrophy. *Cornea*. 2006;25(5):533-539.

100. Heidemann DG, Dunn SP, Chow CY. Comparison of deep lamellar endothelial keratoplasty and penetrating keratoplasty in patients with Fuchs endothelial dystrophy. *Cornea*. 2008;27(2):161-167.
101. Ham L, Dapena I, Moutsouris K, et al. Refractive change and stability after Descemet membrane endothelial keratoplasty. Effect of corneal dehydration-induced hyperopic shift on intraocular lens power calculation. *J Cataract Refract Surg*. 2011;37(8):1455-1464.
102. Lass JH, Gal RL, Dontchev M, et al. Cornea Donor Study Investigator Group. Donor age and corneal endothelial cell loss 5 years after successful corneal transplantation. Specular microscopy ancillary study results. *Ophthalmology*. 2008;115(4):627-632.
103. Ham L, van Luijk C, Dapena I, et al. Endothelial cell density after descemet membrane endothelial keratoplasty: 1- to 2-year follow-up. *Am J Ophthalmol*. 2009;148(4):521-527.
104. Nanavaty MA, Wang X, Shortt AJ. Endothelial keratoplasty versus penetrating keratoplasty for Fuchs endothelial dystrophy. *Cochrane Database Syst Rev*. 2014(2):CD008420.
105. Eye Bank Association of America. 2016 Eye banking statistical report. <https://restoresight.org/what-we-do/publications/statistical-report/>. Accessed March 1, 2018.
106. Price MO, Price FW, Jr. Descemet's membrane endothelial keratoplasty surgery: update on the evidence and hurdles to acceptance. *Curr Opin Ophthalmol*. 2013;24(4):329-335.
107. Yokogawa H, Sanchez PJ, Mayko ZM, Straiko MD, Terry MA. Corneal astigmatism stability in descemet membrane endothelial keratoplasty for fuchs corneal dystrophy. *Cornea*. 2016;35(7):932-937.
108. Veldman PB, Dye PK, Holiman JD, et al. The S-stamp in descemet membrane endothelial keratoplasty safely eliminates upside-down graft implantation. *Ophthalmology*. 2016;123(1):161-164.
109. Ampazas P, Droustas K, Giallourous E, Schroeder FM, Sekundo W. Comparison of 5% sulfur hexafluoride versus 100% air tamponade in descemet membrane endothelial keratoplasty. *Cornea*. 2017;36(10):1189-1194.
110. Moloney G, Petsoglou C, Ball M, et al. Descemetorhexis without grafting for Fuchs endothelial dystrophy-supplementation with topical ripasudil. *Cornea*. 2017;36(6):642-648.
111. Sanchez JC, Infantes Molina EJ, Cantos EA. Descemetorhexis without graft placement: transplant of descemet-free fragments. *Ophthalmology*. 2017;124(11):1620.
112. Kinoshita S, Koizumi N, Ueno M, et al. Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy. *N Engl J Med*. 2018;378(11):995-1003.
113. Turner A, Rabiou M. Patching for corneal abrasion. *Cochrane Database Syst Rev*. 2006(2):CD004764.
114. Federici TJ. The non-antibiotic properties of tetracyclines: clinical potential in ophthalmic disease. *Pharmacol Res*. 2011;64(6):614-623.
115. Watson SL, Secker GA, Daniels JT. The effect of therapeutic human serum drops on corneal stromal wound-healing activity. *Curr Eye Res*. 2008;33(8):641-652.
116. Yoon KC, You IC, Im SK, Jeong TS, Park YG, Choi J. Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis. *Ophthalmology*. 2007;114(9):1637-1642.
117. Alió JL, Abad M, Artola A, Rodriguez-Prats JL, Pastor S, Ruiz-Colecha J. Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers. *Ophthalmology*. 2007;114(7):1286-1293.
118. Aloe L, Tirassa P, Lambiase A. The topical application of nerve growth factor as a pharmacological tool for human corneal and skin ulcers. *Pharmacol Res*. 2008;57(4):253-258.
119. Tan MH, Bryars J, Moore J. Use of nerve growth factor to treat congenital neurotrophic corneal ulceration. *Cornea*. 2006;25(3):352-355.
120. Chikama T, Fukuda K, Morishige N, Nishida T. Treatment of neurotrophic keratopathy with substance-P-derived peptide (FGLM) and insulin-like growth factor I. *Lancet*. 1998;351(9118):1783-1784.
121. Nishida T. The role of fibronectin in corneal wound healing explored by a physician-scientist. *Jpn J Ophthalmol*. 2012;56(5):417-431.
122. Dunn SP, Heidemann DG, Chow CY, et al. Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4. *Ann N Y Acad Sci*. 2010;1194:199-206.
123. Khokhar S, Natung T, Sony P, Sharma N, Agarwal N, Vajpayee RB. Amniotic membrane transplantation in refractory neurotrophic corneal ulcers: a randomized, controlled clinical trial. *Cornea*. 2005;24(6):654-660.
124. Solomon A, Meller D, Prabhasawat P, et al. Amniotic membrane grafts for nontraumatic corneal perforations, descemetoceles, and deep ulcers. *Ophthalmology*. 2002;109(4):694-703.
125. Letko E, Stechschulte SU, Kenyon KR, et al. Amniotic membrane inlay and overlay grafting for corneal epithelial defects and stromal ulcers. *Arch Ophthalmol*. 2001;119(5):659-663.
126. Pachigolla G, Prasher P, Di Pascuale MA, McCulley JP, McHenry JG, Mootha VV. Evaluation of the role of ProKera in the management of ocular surface and orbital disorders. *Eye Contact Lens*. 2009;35(4):172-175.

127. Vote BJ, Elder MJ. Cyanoacrylate glue for corneal perforations: a description of a surgical technique and a review of the literature. *Clin Experiment Ophthalmol.* 2000;28(6):437-442.
128. Arslan S, Aydemir O, Guler M, Dagli AF. Modulation of postoperative scarring with tacrolimus and octreotide in experimental glaucoma filtration surgery. *Curr Eye Res.* 2012;37(3):228-233.
129. Baker R, Urso-Baiarda F, Linge C, Grobbelaar A. Cutaneous scarring: a clinical review. *Dermatol Res Pract.* 2009;2009:625376.
130. Blair J, Hodge W, Al-Ghamdi S, et al. Comparison of antibiotic-only and antibiotic-steroid combination treatment in corneal ulcer patients: double-blinded randomized clinical trial. *Can J Ophthalmol.* 2011;46(1):40-45.
131. Srinivasan M, Mascarenhas J, Rajaraman R, et al. Steroids for Corneal Ulcers Trial Group. Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT). *Arch Ophthalmol.* 2012;130(2):143-150.
132. Holló G. Wound healing and glaucoma surgery: modulating the scarring process with conventional antimetabolites and new molecules. *Dev Ophthalmol.* 2012;50:79-89.
133. Zhong H, Sun G, Lin X, Wu K, Yu M. Evaluation of pirfenidone as a new postoperative antiscarring agent in experimental glaucoma surgery. *Invest Ophthalmol Vis Sci.* 2011;52(6):3136-3142.
134. Prata JA, Jr., Seah SK, Minckler DS, Baerveldt G, Lee PP, Heuer DK. Postoperative complications and short-term outcome after 5-Fluorouracil or mitomycin-C trabeculectomy. *J Glaucoma.* 1995;4(1):25-31.
135. Abraham LM, Selva D, Casson R, Leibovitch I. Mitomycin: clinical applications in ophthalmic practice. *Drugs.* 2006;66(3):321-340.
136. Kim JH, Kim MJ, Kim DY, Kim JY, Tchah H. Recurrent corneal hypertrophic scar after laser-assisted subepithelial keratectomy with mitomycin C treatment. *Cornea.* 2011;30(9):1030-1034.
137. Farid M, Morishige N, Lam L, Wahlert A, Steinert RF, Jester JV. Detection of corneal fibrosis by imaging second harmonic-generated signals in rabbit corneas treated with mitomycin C after excimer laser surface ablation. *Invest Ophthalmol Vis Sci.* 2008;49(10):4377-4383.
138. Ehrlich MI, Phinney RB, Mondino BJ, Pettit TH. Techniques of lamellar keratoplasty. *Int Ophthalmol Clin.* 1988;28(1):24-29.
139. Wood TO, Walker GG. Treatment of band keratopathy. *Am J Ophthalmol.* 1975;80(3 Pt 2):550.
140. Elkins BS, Casebeer JC, Kezirian GM. Sutureless homoplastic lamellar keratoplasty. *J Refract Surg.* 1997;13(2):185-187.
141. Alió JL, Javaloy J, Merayo J, Galal A. Automated superficial lamellar keratectomy augmented by excimer laser masked PTK in the management of severe superficial corneal opacities. *Br J Ophthalmol.* 2004;88(10):1289-1294.
142. Buratto L, Brint SF, Ferrari M. Complications. In: Buratto L, Brint SF, eds. *LASIK: Principles and Techniques.* Thorofare, NJ: SLACK, Inc.; 1998:120-1.
143. Alió JL, Agdeppa MC, Uceda-Montanes A. Femtosecond laser-assisted superficial lamellar keratectomy for the treatment of superficial corneal leukomas. *Cornea.* 2011;30(3):301-307.
144. Rasheed K, Rabinowitz YS. Superficial lamellar keratectomy using an automated microkeratome to excise corneal scarring caused by photorefractive keratectomy. *J Cataract Refract Surg.* 1999;25(9):1184-1187.
145. Najjar DM. Management of band keratopathy with excimer phototherapeutic keratectomy. *Eye (Lond).* 2006;20(2):252.
146. O'Brart DP, Gartry DS, Lohmann CP, Patmore AL, Kerr Muir MG, Marshall J. Treatment of band keratopathy by excimer laser phototherapeutic keratectomy: surgical techniques and long term follow up. *Br J Ophthalmol.* 1993;77(11):702-708.
147. Cavanaugh TB, Lind DM, Cutarelli PE, et al. Phototherapeutic keratectomy for recurrent erosion syndrome in anterior basement membrane dystrophy. *Ophthalmology.* 1999;106(5):971-976.
148. Elsahn AF, Rapuano CJ, Antunes VA, Abdalla YF, Cohen EJ. Excimer laser phototherapeutic keratectomy for keratoconus nodules. *Cornea.* 2009;28(2):144-147.
149. Awdeh RM, Abbey AM, Vroman DT, et al. Phototherapeutic keratectomy for the treatment of subepithelial fibrosis and anterior corneal scarring after descemet stripping automated endothelial keratoplasty. *Cornea.* 2012;31(7):761-763.
150. Stewart OG, Morrell AJ. Management of band keratopathy with excimer phototherapeutic keratectomy: visual, refractive, and symptomatic outcome. *Eye (Lond).* 2003;17(2):233-237.
151. Miller A, Solomon R, Bloom A, Palmer C, Perry HD, Donnenfeld ED. Prevention of recurrent Reis-Bücklers dystrophy following excimer laser phototherapeutic keratectomy with topical mitomycin C. *Cornea.* 2004;23(7):732-735.
152. Das S, Langenbucher A, Seitz B. Excimer laser phototherapeutic keratectomy for granular and lattice corneal dystrophy: a comparative study. *J Refract Surg.* 2005;21(6):727-731.

153. Vinciguerra P, Camesasca FI. Custom phototherapeutic keratectomy with intraoperative topography. *J Refract Surg.* 2004;20(5):S555-563.
154. Ayres BD, Hammersmith KM, Laibson PR, Rapuano CJ. Phototherapeutic keratectomy with intraoperative mitomycin C to prevent recurrent anterior corneal pathology. *Am J Ophthalmol.* 2006;142(3):490-492.
155. Kim TI, Pak JH, Chae JB, Kim EK, Tchah H. Mitomycin C inhibits recurrent Avellino dystrophy after phototherapeutic keratectomy. *Cornea.* 2006;25(2):220-223.
156. Alió JL, Belda JI, Shalaby AM. Correction of irregular astigmatism with excimer laser assisted by sodium hyaluronate. *Ophthalmology.* 2001;108(7):1246-1260.
157. Dinh R, Rapuano CJ, Cohen EJ, Laibson PR. Recurrence of corneal dystrophy after excimer laser phototherapeutic keratectomy. *Ophthalmology.* 1999;106(8):1490-1497.
158. Rapuano CJ. Excimer laser phototherapeutic keratectomy in eyes with anterior corneal dystrophies: short-term clinical outcomes with and without an antihyperopia treatment and poor effectiveness of ultrasound biomicroscopic evaluation. *Cornea.* 2005;24(1):20-31.
159. Najjar DM, Cohen EJ, Rapuano CJ, Laibson PR. EDTA chelation for calcific band keratopathy: results and long-term follow-up. *Am J Ophthalmol.* 2004;137(6):1056-1064.
160. Arjamaa O. EDTA chelation for calcific band keratopathy. *Am J Ophthalmol.* 2005;139(1):216; author reply 216.
161. Lombardo M, De Santo MP, Lombardo G, et al. Surface quality of femtosecond dissected posterior human corneal stroma investigated with atomic force microscopy. *Cornea.* 2012;31(12):1369-1375.
162. Sarayba MA, Ignacio TS, Binder PS, Tran DB. Comparative study of stromal bed quality by using mechanical, IntraLase femtosecond laser 15- and 30-kHz microkeratomes. *Cornea.* 2007;26(4):446-451.
163. Jones MN, Armitage WJ, Ayliffe W, Larkin DF, Kaye SB. Penetrating and deep anterior lamellar keratoplasty for keratoconus: a comparison of graft outcomes in the United Kingdom. *Invest Ophthalmol Vis Sci.* 2009;50(12):5625-5629.
164. Shousha MA, Yoo SH, Kymionis GD, et al. Long-term results of femtosecond laser-assisted sutureless anterior lamellar keratoplasty. *Ophthalmology.* 2011;118(2):315-323.
165. Hoffart L, Proust H, Matonti F, Catanese M, Conrath J, Ridings B. Femtosecond-assisted anterior lamellar keratoplasty [in French]. *J Fr Ophthalmol.* 2007;30(7):689-694.
166. Mosca L, Fasciani R, Tamburelli C, et al. Femtosecond laser-assisted lamellar keratoplasty: early results. *Cornea.* 2008;27(6):668-672.
167. Utine CA, Tzu JH, Akpek EK. Lamellar keratoplasty using gamma-irradiated corneal lenticules. *Am J Ophthalmol.* 2011;151(1):170-174.
168. Daoud YJ, Smith R, Smith T, Akpek EK, Ward DE, Stark WJ. The intraoperative impression and postoperative outcomes of gamma-irradiated corneas in corneal and glaucoma patch surgery. *Cornea.* 2011;30(12):1387-1391.
169. Stevenson W, Cheng SF, Emami-Naeini P, et al. Gamma-irradiation reduces the allogenicity of donor corneas. *Invest Ophthalmol Vis Sci.* 2012;53(11):7151-7158.
170. Jhanji V, Sharma N, Vajpayee RB. Management of keratoconus: current scenario. *Br J Ophthalmol.* 2011;95(8):1044-1050.
171. Reinhart WJ, Musch DC, Jacobs DS, Lee WB, Kaufman SC, Shtein RM. Deep anterior lamellar keratoplasty as an alternative to penetrating keratoplasty a report by the american academy of ophthalmology. *Ophthalmology.* 2011;118(1):209-218.
172. Feizi S, Javadi MA, Jamali H, Mirbabae F. Deep anterior lamellar keratoplasty in patients with keratoconus: big-bubble technique. *Cornea.* 2010;29(2):177-182.
173. Buzzonetti L, Laborante A, Petrocelli G. Refractive outcome of keratoconus treated by combined femtosecond laser and big-bubble deep anterior lamellar keratoplasty. *J Refract Surg.* 2011;27(3):189-194.
174. Farid M, Steinert RF. Deep anterior lamellar keratoplasty performed with the femtosecond laser zigzag incision for the treatment of stromal corneal pathology and ectatic disease. *J Cataract Refract Surg.* 2009;35(5):809-813.
175. Ardjomand N, Hau S, McAlister JC, et al. Quality of vision and graft thickness in deep anterior lamellar and penetrating corneal allografts. *Am J Ophthalmol.* 2007;143(2):228-235.
176. Al-Torbak AA, Al-Motowa S, Al-Assiri A, et al. Deep anterior lamellar keratoplasty for keratoconus. *Cornea.* 2006;25(4):408-412.
177. Feizi S, Javadi MA, Rastegarpour A. Visual acuity and refraction after deep anterior lamellar keratoplasty with and without successful big-bubble formation. *Cornea.* 2010;29(11):1252-1255.
178. Fontana L, Parente G, Sincich A, Tassinari G. Influence of graft-host interface on the quality of vision after deep anterior lamellar keratoplasty in patients with keratoconus. *Cornea.* 2011;30(5):497-502.
179. Fontana L, Parente G, Tassinari G. Clinical outcomes after deep anterior lamellar keratoplasty using the big-bubble technique in patients with keratoconus. *Am J Ophthalmol.* 2007;143(1):117-124.

180. Han DC, Mehta JS, Por YM, Htoon HM, Tan DT. Comparison of outcomes of lamellar keratoplasty and penetrating keratoplasty in keratoconus. *Am J Ophthalmol*. 2009;148(5):744-751.
181. Javadi MA, Feizi S, Yazdani S, Mirbabae F. Deep anterior lamellar keratoplasty versus penetrating keratoplasty for keratoconus: a clinical trial. *Cornea*. 2010;29(4):365-371.
182. Smadja D, Colin J, Krueger RR, et al. Outcomes of deep anterior lamellar keratoplasty for keratoconus: learning curve and advantages of the big bubble technique. *Cornea*. 2012;31(8):859-863.
183. Kubaloglu A, Sari ES, Unal M, et al. Long-term results of deep anterior lamellar keratoplasty for the treatment of keratoconus. *Am J Ophthalmol*. 2011;151(5):760-767.
184. Cheng YY, Visser N, Schouten JS, et al. Endothelial cell loss and visual outcome of deep anterior lamellar keratoplasty versus penetrating keratoplasty: a randomized multicenter clinical trial. *Ophthalmology*. 2011;118(2):302-309.
185. Fogla R, Padmanabhan P. Results of deep lamellar keratoplasty using the big-bubble technique in patients with keratoconus. *Am J Ophthalmol*. 2006;141(2):254-259.
186. Kubaloglu A, Koytak A, Sari ES, Akyol S, Kurnaz E, Ozerturk Y. Corneal endothelium after deep anterior lamellar keratoplasty and penetrating keratoplasty for keratoconus: a four-year comparative study. *Indian J Ophthalmol*. 2012;60(1):35-40.
187. Sarnicola V, Toro P, Sarnicola C, Sarnicola E, Ruggiero A. Long-term graft survival in deep anterior lamellar keratoplasty. *Cornea*. 2012;31(6):621-626.
188. Olson EA, Tu EY, Basti S. Stromal rejection following deep anterior lamellar keratoplasty: implications for postoperative care. *Cornea*. 2012;31(9):969-973.
189. Parmar P, Salman A, Jesudasan CA. Visual outcome and corneal topography after eccentric "shaped" corneal grafts. *Cornea*. 2009;28(4):379-384.
190. Huang T, Wang Y, Ji J, Gao N, Chen J. Evaluation of different types of lamellar keratoplasty for treatment of peripheral corneal perforation. *Graefes Arch Clin Exp Ophthalmol*. 2008;246(8):1123-1131.
191. Afshari NA, Duncan SM, Tanhehco TY, Azar DT. Optimal size and location for corneal rotational autografts: a simplified mathematical model. *Arch Ophthalmol*. 2006;124(3):410-413.
192. Bertelmann E, Hartmann C, Scherer M, Rieck P. Outcome of rotational keratoplasty: comparison of endothelial cell loss in autografts vs allografts. *Arch Ophthalmol*. 2004;122(10):1437-1440.
193. Mashor RS, Rootman DB, Bahar I, Singal N, Slomovic AR, Rootman DS. Outcomes of deep anterior lamellar keratoplasty versus intralase enabled penetrating keratoplasty in keratoconus. *Can J Ophthalmol*. 2011;46(5):403-407.
194. Chamberlain WD, Rush SW, Mathers WD, Cabezas M, Fraunfelder FW. Comparison of femtosecond laser-assisted keratoplasty versus conventional penetrating keratoplasty. *Ophthalmology*. 2011;118(3):486-491.
195. Chan CC, Ritenour RJ, Kumar NL, Sansanayudh W, Rootman DS. Femtosecond laser-assisted mushroom configuration deep anterior lamellar keratoplasty. *Cornea*. 2010;29(3):290-295.
196. Ignacio TS, Nguyen TB, Chuck RS, Kurtz RM, Sarayba MA. Top hat wound configuration for penetrating keratoplasty using the femtosecond laser: a laboratory model. *Cornea*. 2006;25(3):336-340.
197. Kutzscher EM, Sorenson AL, Goodman DF. Penetrating keratoplasty performed by residents. *Arch Ophthalmol*. 2004;122(9):1333-1336.
198. Moorthy S, Graue E, Jhanji V, Constantinou M, Vajpayee RB. Microbial keratitis after penetrating keratoplasty: impact of sutures. *Am J Ophthalmol*. 2011;152(2):189-194 e182.
199. Hood CT, Lee BJ, Jeng BH. Incidence, occurrence rate, and characteristics of suture-related corneal infections after penetrating keratoplasty. *Cornea*. 2011;30(6):624-628.
200. Chamberlain W, Omid N, Lin A, Farid M, Gaster RN, Steinert RF. Comparison of corneal surface higher-order aberrations after endothelial keratoplasty, femtosecond laser-assisted keratoplasty, and conventional penetrating keratoplasty. *Cornea*. 2012;31(1):6-13.
201. Armitage WJ, Dick AD, Bourne WM. Predicting endothelial cell loss and long-term corneal graft survival. *Invest Ophthalmol Vis Sci*. 2003;44(8):3326-3331.
202. Park CY, Lee JK, Gore PK, Lim CY, Chuck RS. Keratoplasty in the United States: a 10-year review from 2005 through 2014. *Ophthalmology*. 2015;122(12):2432-2442.
203. Aldave AJ, DeMatteo J, Glasser DB, et al. Report of the Eye Bank Association of America medical advisory board subcommittee on fungal infection after corneal transplantation. *Cornea*. 2013;32(2):149-154.
204. Edelstein SL, DeMatteo J, Stoeger CG, Macsai MS, Wang CH. Report of the Eye Bank Association of America medical review subcommittee on adverse reactions reported From 2007 to 2014. *Cornea*. 2016;35(7):917-926.
205. Vislisel JM, Goins KM, Wagoner MD, et al. Incidence and outcomes of positive donor corneoscleral rim fungal cultures after keratoplasty. *Ophthalmology*. 2017;124(1):36-42.

206. Brothers KM, Shanks RMQ, Hurlbert S, Kowalski RP, Tu EY. Association between fungal contamination and eye bank-prepared endothelial keratoplasty tissue: temperature-dependent risk factors and antifungal supplementation of optisol-gentamicin and streptomycin. *JAMA Ophthalmol.* 2017;135(11):1184-1190.
207. Wilhelmus KR, Hassan SS. The prognostic role of donor corneoscleral rim cultures in corneal transplantation. *Ophthalmology.* 2007;114(3):440-445.
208. Keyhani K, Seedor JA, Shah MK, Terraciano AJ, Ritterband DC. The incidence of fungal keratitis and endophthalmitis following penetrating keratoplasty. *Cornea.* 2005;24(3):288-291.
209. Barber JC. Keratoprosthesis: past and present. *Int Ophthalmol Clin.* 1988;28(2):103-109.
210. Cardona H, DeVoe AG. Prostrokeratoplasty. *Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol.* 1977;83(2):271-280.
211. Falcinelli G, Falsini B, Taloni M, Colliardo P. Modified osteo-odonto-keratoprosthesis for treatment of corneal blindness: long-term anatomical and functional outcomes in 181 cases. *Arch Ophthalmol.* 2005;123(10):1319-1329.
212. Hicks CR, Crawford GJ, Tan DT, et al. AlphaCor cases: comparative outcomes. *Cornea.* 2003;22(7):583-590.
213. Pujari S, Siddique SS, Dohlman CH, Chodosh J. The Boston keratoprosthesis type II: the Massachusetts Eye and Ear Infirmary experience. *Cornea.* 2011;30(12):1298-1303.
214. Aldave AJ, Kamal KM, Vo RC, Yu F. The Boston type I keratoprosthesis: improving outcomes and expanding indications. *Ophthalmology.* 2009;116(4):640-651.
215. Aldave AJ, Sangwan VS, Basu S, et al. International results with the Boston type I keratoprosthesis. *Ophthalmology.* 2012;119(8):1530-1538.
216. Zerbe BL, Belin MW, Ciolino JB. Boston Type 1 Keratoprosthesis Study Group. Results from the multicenter Boston Type 1 Keratoprosthesis Study. *Ophthalmology.* 2006;113(10):1779.
217. Greiner MA, Li JY, Mannis MJ. Longer-term vision outcomes and complications with the Boston type 1 keratoprosthesis at the University of California, Davis. *Ophthalmology.* 2011;118(8):1543-1550.
218. Harissi-Dagher M, Dohlman CH. The Boston Keratoprosthesis in severe ocular trauma. *Can J Ophthalmol.* 2008;43(2):165-169.
219. Iyer G, Srinivasan B, Gupta J, et al. Boston keratoprosthesis for keratopathy in eyes with retained silicone oil: a new indication. *Cornea.* 2011;30(10):1083-1087.
220. Khan BF, Harissi-Dagher M, Pavan-Langston D, Aquavella JV, Dohlman CH. The Boston keratoprosthesis in herpetic keratitis. *Arch Ophthalmol.* 2007;125(6):745-749.
221. Pavan-Langston D, Dohlman CH. Boston keratoprosthesis treatment of herpes zoster neurotrophic keratopathy. *Ophthalmology.* 2008;115(2 Suppl):S21-23.
222. Akpek EK, Harissi-Dagher M, Petrarca R, et al. Outcomes of Boston keratoprosthesis in aniridia: a retrospective multicenter study. *Am J Ophthalmol.* 2007;144(2):227-231.
223. Sayegh RR, Ang LP, Foster CS, Dohlman CH. The Boston keratoprosthesis in Stevens-Johnson syndrome. *Am J Ophthalmol.* 2008;145(3):438-444.
224. Bersudsky V, Blum-Hareuveni T, Rehany U, Rumelt S. The profile of repeated corneal transplantation. *Ophthalmology.* 2001;108(3):461-469.
225. Aquavella JV, Gearing MD, Akpek EK, McCormick GJ. Pediatric keratoprosthesis. *Ophthalmology.* 2007;114(5):989-994.
226. Fung SSM, Jabbour S, Harissi-Dagher M, et al. Visual outcomes and complications of type I Boston keratoprosthesis in children: a retrospective multicenter study and literature review. *Ophthalmology.* 2018;125(2):153-160.
227. Ciolino JB, Ament JW, Zerbe BL, Belin MW. Etiology of keratoprosthesis loss: results from the Boston Keratoprosthesis Multicenter Study. *Invest Ophthalmol Vis Sci.* 2008;49:E-Abstract 5712.
228. Verdejo-Gomez L, Pelaez N, Gris O, Guell JL. The Boston Type I keratoprosthesis: an assessment of its efficacy and safety. *Ophthalmic Surg Lasers Imaging.* 2011;42(6):446-452.
229. Aravena C, Yu F, Aldave AJ. Long-term visual outcomes, complications, and retention of the Boston type I keratoprosthesis. *Cornea.* 2018;37(1):3-10.
230. Dohlman CH, Grosskreutz CL, Chen TC, et al. Shunts to divert aqueous humor to distant epithelialized cavities after keratoprosthesis surgery. *J Glaucoma.* 2010;19(2):111-115.
231. Patel S, Takusagawa H, Shen L, Dohlman C, Grosskreutz C. Long-term complications associated with glaucoma drainage devices and Boston keratoprosthesis. *Am J Ophthalmol.* 2012;154(1):207-208; author reply 208-209.
232. Kamyar R, Weizer JS, de Paula FH, et al. Glaucoma associated with Boston type I keratoprosthesis. *Cornea.* 2012;31(2):134-139.
233. Alexander JK, Basak SK, Padilla MD, Yu F, Aldave AJ. International outcomes of the Boston type I keratoprosthesis in Stevens-Johnson syndrome. *Cornea.* 2015;34(11):1387-1394.

234. Biber JM, Skeens HM, Neff KD, Holland EJ. The Cincinnati procedure: technique and outcomes of combined living-related conjunctival limbal allografts and keratolimbal allografts in severe ocular surface failure. *Cornea*. 2011;30(7):765-771.
235. Srikumaran D, Munoz B, Aldave AJ, et al. Long-term outcomes of boston type 1 keratoprosthesis implantation: a retrospective multicenter cohort. *Ophthalmology*. 2014;121(11):2159-2164.
236. Yaghouti F, Nouri M, Abad JC, Power WJ, Doane MG, Dohlman CH. Keratoprosthesis: preoperative prognostic categories. *Cornea*. 2001;20(1):19-23.
237. Barnes SD, Dohlman CH, Durand ML. Fungal colonization and infection in Boston keratoprosthesis. *Cornea*. 2007;26(1):9-15.
238. Mazzotta C, Traversi C, Baiocchi S, Barabino S, Mularoni A. Phenotypic spectrum of granular corneal dystrophy type II in two italian families presenting an unusual granular corneal dystrophy type I clinical appearance. *Case Rep Ophthalmol Med*. 2015;2015:703418.
239. Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. *Lancet Glob Health*. 2017;5(12):e1221-e1234.
240. Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. *Bull World Health Organ*. 2001;79(3):214-221.
241. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. *Br J Ophthalmol*. 2012;96(5):614-618.
242. Oliva MS, Schottman T, Gulati M. Turning the tide of corneal blindness. *Indian J Ophthalmol*. 2012;60(5):423-427.